Supplemental Online Content

MARVEL Trial Authors for the MARVEL Investigators. Methylprednisolone as adjunct to endovascular thrombectomy for large vessel occlusion stroke: the MARVEL randomized clinical trial. *JAMA*. doi:10.1001/jama.2024.0626

This supplemental material has been provided by the authors to give readers additional information about their work.

List of Investigators

Enrolling Clinical Centers (number of patients enrolled), Principal Investigators

Qujing First People's Hospital (133) Yifei Chen;

Longyan First Hospital (126) Chong Zheng;

Xinqiao Hospital and The Second Affiliated Hospital (98) Wenjie Zi;

Jingdezhen NO.1 People's Hospital (78) Shunfu Jiang;

The First Affiliated Hospital of University of South China (48) Zhongfan Ruan;

Jiangmen Central Hospital (46) Min Zhang;

Hospital 302 Attached to Anshun Group (44) Dengwen Song;

Guangyuan Central Hospital (41) Xiaojun Luo;

Qian Xi Nan People's Hospital (40) Yaoyu Tian;

Dali Bai Autonomous Prefecture People's Hospital (36) Mei Yang;

People's Hospital of Wushen County (36) Shenglin Deng;

The people's Hospital of Hechi and the Hechi Hospital Affiliated to Youjiang Medical University For Nationalities (35) Shirong Wei;

Chongzhou Hospital (34) Youlin Wu;

Mianyang Central Hospital (33) Yufeng Tang;

Chongqing University Fuling Hospital (32) De Yang;

Ganzhou People's Hospital (32) Guoyong Zeng;

Meishan Second People's Hospital (31) Xiaolin Tan;

Xingyi People's Hospital (31) Daoyou Cheng;

Wuhan Hospital of Traditional Chinese And Western Medicine (31) Wenhua Liu;

Guiping People's Hospital (30) Wencheng He;

Yunyang County People's Hospital (27) Tieying Cai;

People's Hospital of Chongqing Banan District (24) Chengde Pan;

Suining First People's Hospital (24) Jiasheng Liao;

The People's Hospital Of Leshan (24) Bo Lei;

Affiliated Hospital of North Sichuan Medical College (24) Shengxiong Pu;

Jiangmen Wuyi Hospital of traditional Chinese Medicine (22) Zhenglong Jin;

The Affiliated Hospital of Southwest Medical University (20) Jinglun Li;

Jiujiang University Affiliated Hospital (20) Zhongbin Xia;

The People's Hospital Of Danzhai (20) Guling Zhang;

Sichuan Mianyang 404 Hospital (19) Jun Luo;

Shanxi Provincial People's Hospital (19) Yaxuan Sun;

Chongqing University Qianjiang Hospital (16) Xiaoping Xiong;

Yaan People's Hospital (16) Jian Wang;

Bazhong Central Hospital (16) Bo Li;

Sichuan Science City Hospital (16) Yuqi Peng;

Zhangjiagang First Peole's Hospital (16) Kechun Chen;

Xiangyang No.1 People's Hospital (16) Peiyang Zhou;

The Affiliated Baiyun Hospital of Guizhou Medical University (16) Xinyuan Huang;

Jieyang People's Hospital (16) Shiwei Luo;

Zhejiang Provincial People's Hospital Bijie Hospital (16) Jie Zhang;

Xiangzhou District People's Hospital (15) Yuanjun Shan;

Hubei Provincial Hospital of TCM (14) Jie Pu;

Xi Chang People's Hospital (13) Yang Ni;

Taihe Hospital of Traditional Chinese Medicine (13) Zongtao Liu;

The third Hospital of Mianyang (12) Xin Zou;

Chengdu Second People's Hospital (12) Changchuan Wu;

Dazhou Central Hospital (10) Jiazuo Liu;

The 924th Hospital of The Chinese People's Liberation Army (10) Li Qi;

Yuebei People's Hospital (10) Junbin Chen;

Weihai Municipal Hospital (9) Pengfei Wang;

Chognqing Sanbo Changan Hospital (8) Jianfang Luan;

The First People's Hospital of Yunnan Province (8) Da Liu;

Xianyang Hospital of Yan'an University (8) Bo Song;

Dushu Lake Hospital Affiliated to Soochow University and The Medical Center of Soochow University (8) Yonggang Hao;

Zigong First People's Hospital (8) Tao Qiu;

Jintang People's Hospital (8) Kuiyun Wang;

Changzhi People's Hospital (8) Zuopeng Li;

The People's Hospital of Pingchang (8) Junsheng Liu;

Ningbo Medical Center Lihuili Hospital (8) Zhenqiang Li;

Shenqiu County People's Hospital (8) Yanling Li;

People's Hospital of Zunyi City Bo Zhou District (8) Shuang Yang;

Nanping First Hospital (8) Xiaoli Lin;

Affiliated Hospital of Chengdu University (8) Wen Cheng;

The Third People's Hospital of Guiyang (7) Anqiang Chen;

Dianjiang People's Hospital of Chongqing (5) Shiqiang Yan;

Yongchuan Hospital of Chongqing Medical University (4) Shudong Liu;

The People's Hospital of Kaizhou District (4) Jie Du;

Mianzhu People's Hospital (4) Zhuo Chen;

Meishan City People's Hospital (4) Bo Song;

Xian XD Group Hospital (4) Li Yao;

The Second Affiliated Hospital of Guangxi Medical University (4) Deyan Kong;

Chongqing Fengdu People's Hospital (3) Hongjun Wang;

The First Bethune Hospital of Jilin University (3) Shouchun Wang;

Guiyang Huaxi District People's Hospital (3) Xunfeng Zhu;

The Third People's Hospital of Hubei Province (2) Yue Wan;

The Second People's Hospital of Mengjin District (2) Haojin Zhao;

GaoZhou People's Hospital (2) Qingchun Mou;

Luxian People's Hospital (1) Ling Dai;

The People's Hospital of Dujiangyan (1) Shui Yu;

Songyuan Jinlin Oilfield Hospital (1) Dongsheng Ju;

Maoming Hospital of traditional Chinese Medicine (1) Wenguo Huang;

Houjie Hospital of Dongguan (1) Yihong Huang.

eMethods

eMethod 1. Detailed Inclusion and Exclusion Criteria:

Inclusion criteria

1. Age ≥ 18 years;
2. The time from onset to randomization was within 24 hours;
3. Anterior circulation ischemic stroke was preliminarily determined according to clinical symptoms or imaging examination;
4. Baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 6
5. Baseline Alberta Stroke Program Early CT Score (ASPECTS)≥ 3;
6. Computed tomography angiography (CTA) /magnetic resonance angiography (MRA) /digital subtraction angiography (DSA) confirmed occlusion of the intracranial segment of the internal carotid artery or middle cerebral artery, and decision to undergo endovascular therapy;
7. Written informed consent signed by patient or their family member.

Exclusion Criteria:

Patients meeting any of the following criteria were excluded from study enrolment.

- Intracranial hemorrhage confirmed by cranial computed tomography (CT) or magnetic resonance imaging (MRI);

- mRS score ≥ 2 before onset;
- Pregnant or lactating women;
- Allergic to contrast agents;
- Allergic to glucocorticoids;
- Participating in other clinical trials;
- Systolic blood pressure > 185 mmHg or diastolic pressure > 110 mmHg, and unable to control with oral antihypertensive drugs;
- Genetic or acquired bleeding diathesis, lack of anticoagulant factors; or oral anticoagulants and INR > 1.7;
- Blood sugar < 2.8 mmol/L (50 mg/dl) or > 22.2 mmol/L (400 mg/dl), platelet < 90 x 10^9/L;
- Arterial tortuosity such that the thrombectomy device cannot reach the target vessel;
- Bleeding history (gastrointestinal and urinary tract bleeding) in recent 1 month;
- Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate < 30 ml/min or serum creatinine > 220 umol/L [2.5 mg/ dL]);
- Life expectancy due to any advanced disease < 6 months;
- Follow-up is not expected to be completed;
- Intracranial aneurysm and arteriovenous malformation;

- Brain tumor with imaging mass effect;
- Severe systemic infectious disease.

Inclusion and exclusion criteria will be assessed based on information available during the screening period.

eMethod 2. Definition of Analyzed Population

Full Analysis Set as randomized

The full analysis set (FAS) as randomized includes all patients randomized into the trial except 7 patients who withdrew consent immediately after randomization. The analysis of the primary endpoint will be a complete case analysis of the FAS which patients missing day 90 assessments will be censored (deleted).

The Per-Protocol (PP) Population

The PP population is defined as the subset of the ITT population excluding major protocol violators deemed to have the potential to affect patient outcome in terms of efficacy.

The PP population includes patients who actually received the assigned treatment and do not have major protocol violations or deviations. Major protocol violations or deviations were identified in a blinded fashion prior to database lock. More specifically, patients with any one of the following criteria were excluded from the PP population. These deviations were determined based on the medical monitors' records, as well as programmatically, using the following criteria at a minimum:

- Received but did not complete treatment with study drug, or dose of study drug administered outside recommended dose.
- Received any additional anti-platelet therapy (e.g., oral clopidogrel)
- Violated inclusion or exclusion criteria.

A list of patients to be excluded from the randomized patients to create the PP-Efficacy analysis will be established and validated by the Steering Committee prior to unblinding.

Safety Population

The Safety Population included all patients who received any amount of study drug. In case of violation of the randomization scheme, patients were classified according to the treatment they received. Patients were assigned to the different populations prior to unblinding of the database. Patients who withdrew informed consent immediately after randomization and did not to receive any treatment were excluded from the Safety Populations. The safety population is identical to the ITT population in this study.

eMethod 3. Handling of Missing Values and Sensitivity Analyses

The primary analysis of the primary endpoint was a complete case analysis under which patients missing day 90 assessments were censored (deleted).

To assess the influence of the missing primary endpoints on the treatment effect estimate, sensitivity analyses were performed using the same statistical methods as in the primary analysis, considering several situations:

(1) Worst-case scenario:

All patients with a missing primary endpoint were considered as a mRS of 6 in both treatment groups.

(2) Best-case scenario:

All patients with a missing primary endpoint were considered as a mRS of 0 in both treatment groups.

(3) Multiple imputation:

Missing mRS score were imputed using the multiple imputation method via SAS PROC MI. The imputation procedure was performed under the missing-at-random (MAR) assumption. Fully conditional method (FCS) was used to predict missing mRS score by fitting an ordered logistic regression model with the following predictors: treatment group, age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location, and last observed NIHSS if available. The seed was 128. A total of 10 imputed datasets were generated. GenOR was estimated for each dataset separately, and pooled together to calculate the final pooled genOR and 95% confidence interval using Robin's role.

(4) Proportional odds model. A proportional odds model was employed in the sensitivity analysis. Both the unadjusted and adjusted results were presented. The adjusted model included age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS, the use of intravenous thrombolysis, time from onset to randomization, and occlusion location as covariates.

(5) Proportional odds model with random effect: A proportional odds model with random effect was fitted to estimate the common odds ratio between the methylprednisolone and placebo treatment with treatment as fixed effect, age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location as covariates, and the center as a random effect.

(6) Post-hoc worst-best scenario analysis: Patients with a missing primary endpoint in the placebo group were considered as a mRS of 0 while patients with a missing primary outcome in the methylprednisolone group were considered a mRS of 6.

eTables

eTable 1. Demographic and Clinical Characteristics of Patients at Baseline (Per-Protocol Population). [a]

Characteristics	Methylprednisolone (N=761)	Placebo (N=779)
Age, median (IQR), y	68.0 (59.0,75.0)	69.0 (59.0,77.0)
Fale sex, No. (%)	435 (57.2)	435 (55.8)
Medical history, No. (%)		
Hypertension	455 (59.8)	485 (62.3)
Hyperlipidemia	245 (32.2)	225 (28.9)
Atrial fibrillation	313 (41.1)	323 (41.5)
Coronary heart disease	137 (18.0)	157 (20.2)
Valvular heart disease	100 (13.1)	105 (13.5)
Diabetes mellitus	158 (20.8)	137 (17.6)
Transient ischemic attack	6 (0.8)	4 (0.5)
Cerebral ischemia	118 (15.5)	103 (13.2)
Intracranial hemorrhage	9 (1.2)	8 (1.0)
Smoking	217 (28.5)	217 (27.9)
Pre-stroke Modified Rankin Scale score, No. (%)		
0	736 (96.7)	765 (98.2)
1	25 (3.3)	14 (1.8)
Baseline NIHSS score (IQR) [b]	19.0 (16.0, 21.0)	19.0 (16.0, 21.0)
Baseline ASPECTS value, median (IQR) [c]	6.0 (4.0, 7.0)	6.0 (4.0, 7.0)
Side of hemisphere, No./total (%) [d]		
left	383/761 (50.3)	386/778 (49.6)
right	378/761 (49.7)	392/778 (50.4)
TOAST etiology, No. (%) [e]		
LAA	284 (37.3)	311 (39.9)
CE	381 (50.1)	363 (46.6)
Other	26 (3.4)	38 (4.9)
Unknown	70 (9.2)	67 (8.6)
Occlusion site on CT or MR angiography, No. (%)		
Intracranial internal carotid artery	245 (32.2)	265 (34.0)
M1 middle cerebral artery segment	421 (55.3)	398 (51.1)
M2 middle cerebral artery segment	95 (12.5)	116 (14.9)
IV thrombolysis, No. (%)	272 (35.7)	314 (40.3)
Median time from onset to puncture, median (IQR), min	343.0 (230.0, 605.0)	352.0 (237.0, 577.0)
Median time from onset to randomization, median (IQR), min	346.0 (235.0, 604.0)	357.0 (236.0, 572.0)
Median time from onset to recanalization, median (IQR), min [f]	423.0 (310.0, 689.0	435.0 (311.0, 668.0)
Median time from randomization to initial treatment, median (IQR), min [g]	8.0 (6.0, 13.0)	8.0 (6.0, 13.0)
Median systolic blood pressure at hospital arrival, median (IQR), mm Hg	142.0 (127.0, 160.0)	145.0 (127.0, 160.0)
Median diastolic blood pressure at hospital arrival, median (IQR), mm Hg	82.0 (74.0, 92.0)	84.0 (74.0, 94.0)
Median glucose level at hospital arrival, median (IQR), mmol/liter [h]	7.2 (6.2, 8.9)	7.1 (6.0, 8.6)

Abbreviations: ASPECTS, Alberta Stroke Program Early Computed Tomography Score; CI, confidence interval; CT, Computed Tomography; IQR, interquartile range; MR, Magnetic Resonance; NIHSS National Institutes of Health Stroke Scale; IV, intravenous; M1, main trunk of the middle cerebral artery; M2, segment first-order branch of the main trunk.

[a] There was no significant difference between the two groups.

[b] Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurological deficits.

[c] The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is an imaging measure of the extent of ischemic stroke. Scores range from 0 to 10, with higher scores indicating a smaller infarct core. Listed are values for the core laboratory assessment.

[d] Data on Side of Hemisphere at baseline were missing for 1 patient in placebo group.

[e] The TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification system is a widely used method for classifying ischemic strokes and transient ischemic attacks (TIAs). It divides ischemic strokes and TIAs into five subtypes based on their likely causes: Large-artery atherosclerosis (LAA), Cardioembolism (CE), Small-artery occlusion (SAO), Other determined etiology (Other), Undetermined etiology (Unknown).

[f] Data on the time from onset to recanalization at baseline were missing for 1 patient in Placebo group.

[g] Data on the time from randomization to initial treatment at baseline were missing for 1 patient in the Placebo group.

[h] To convert the values to milligrams per deciliter, divide by 0.05551. Data were missing for 94 patients in the Methylprednisolone group and 99 patients in the Placebo group.

eTable 2. Detailed Analysis of Primary and Secondary Outcomes (Full Analysis set as randomized). [a]

Outcomes	Methylprednisolone (N=839)	Placebo (N=841)	Treatment Effect	Unadjusted Value (95% CI)	P	Adjusted Value (95% CI) †	p
Primary efficacy outcomes							
mRS score at 90 days — Win proportion (%) [b]	43.96	39.25	GenOR [c]	1.12(0.98 to 1.28)	0.09	1.10 (0.96 to 1.25)	0.17
			cOR	1.16 (0.98 to 1.37)	0.09	1.06 (1 to 1.13)	0.0496
Secondary efficacy outcomes							
mRS score of 0 to 4 at 90 days, No./total (%)	597/835 (71.5)	555/838 (66.2)	Risk ratio	1.08 (1.01 to 1.15)	0.02	1.07 (1.00 to 1.14)	0.04
			Risk difference	0.05 (0.01 to 0.1)	0.02	0.05 (0.01 to 0.08)	0.004
			Odds ratio	1.28 (1.04 to 1.57)	0.02	1.24 (1.07 to 1.43)	0.004
mRS score of 0 to 3 at 90 days, No./total (%)	496/835 (59.4)	459/838 (54.8)	Risk ratio	1.08 (1 to 1.18)	0.056	1.07 (0.98 to 1.16)	0.11
			Risk difference	0.05 (0 to 0.09)	0.056	0.04 (0.01 to 0.07)	0.02
			Odds ratio	1.21 (1 to 1.47)	0.06	1.17 (1.02 to 1.34)	0.02
mRS score of 0 to 2 at 90 days, No./total (%)	368/835 (44.1)	343/838 (40.9)	Risk ratio	1.08 (0.96 to 1.20)	0.19	1.07 (0.95 to 1.19)	0.26
			Risk difference	0.03 (-0.02 to 0.08)	0.19	0.03 (-0.01 to 0.06)	0.11
			Odds ratio	1.14 (0.94 to 1.38)	0.19	1.12 (0.97 to 1.28)	0.11
mRS score of 0 to 1 at 90 days, No./total (%)	223/835 (26.7)	222/838 (26.5)	Risk ratio	1.01 (0.86 to 1.18)	0.92	0.99 (0.84 to 1.16)	0.89
			Risk difference	0 (-0.04 to 0.04)	0.92	0 (-0.03 to 0.03)	0.85
			Odds ratio	1.01 (0.81 to 1.26)	0.92	0.98 (0.84 to 1.15)	0.85
NIHSS score at 5-7 days or earlier charge, median (IOR) [d]	11.0 (4.0 to 23.0)	12.0 (4.0 to 28.0)	Win Ratio	1.08 (0.96 to 1.21)	0.20	1.07 (0.95 to 1.20)	0.25
EQ-5D-VAS score at 90 days, median (IQR) [e]	55.0 (5.0 to 80.0)	50.0 (0.0 to 80.0)	Win Ratio	1.13(1.00 to 1.28)	0.051	1.11(0.98 to 1.25)	0.10

Abbreviations: mRS, modified Rankin scale; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; an EQ-5D-VAS, EuroQol-5 VAS score.

[a] The widths of the confidence intervals for the secondary outcomes were not adjusted for multiple comparisons, and the reported confidence intervals should not be used for hypothesis testing.

[b] The modified Rankin Scale of functional disability ranges from 0 (no symptoms) to 6 (death). Data were missing for four patients in the methylprednisolone group and 3 patients in the placebo group. The win proportion was calculated by the number of wins in the Methylprednisolone group over the Placebo group in mRS among all possible pairs of mRS taking one patient from the Methylprednisolone group and one patient from the Placebo group divided by the total number of pairs.

[c] The GenOR indicated the probability of modified Rankin Scale score was lower than the other group. Generalized Odds Ratio, common odds ratio, risk ratio, and risk difference were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method and were not adjusted for multiple comparisons.

[d] Scores on the NIHSS range from 0 to 42, with higher values reflecting more severe neurologic impairment.

[e] The EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) visual-analogue scale is a continuous scale measure of self-reported quality of life. Scores range from 0 to 100, with 0 indicating the worst possible quality of life and 100 the best possible quality of life. Data were missing for four patients in the methylprednisolone group and 3 patients in the placebo group.

eTable 3. Primary and Secondary Efficacy Outcomes (Per-Protocol Population) [a]

Outcome	Methylprednisolone (N=761)	Placebo (N=779)	Treatment Effect	Unadjusted Value (95% CI)	P	Adjusted Value (95% CI)	p
Primary efficacy outcomes							
mRS score at 90 days, Win probability (%) [b]	44.29	39.34	GenOR [c]	1.13 (0.98 to 1.29)	0.09	1.11 (0.96 to 1.27)	0.15
			cOR	1.17 (0.98 to 1.39)	0.09	1.07 (1 to 1.14)	0.04
Secondary efficacy outcomes							
mRS score of 0 to 4 at 90 days, No. (%)	565 (74.2)	530 (68.0)	Risk ratio	1.09 (0.02 to 1.16)	0.007	1.08 (1.01 to 1.15)	0.02
			Risk difference	0.06 (0.02 to 0.11)	0.007	1.31 (1.12 to 1.53)	0.001
			Odds ratio	1.35 (1.09 to 1.69)	0.007	0.06 (0.02 to 0.09)	0.001
mRS score of 0 to 3 at 90 days, No. (%)	469 (61.6)	441 (56.6)	Risk ratio	1.09 (1.00 to 1.18)	0.045	1.08 (0.99 to 1.17)	0.09
			Risk difference	0.05 (0 to 0.10)	0.045	0.04 (0.01 to 0.08)	0.02
			Odds ratio	1.23 (1 to 1.51)	0.045	1.2 (1.04 to 1.38)	0.02
mRS score of 0 to 2 at 90 days, No./total (%)	347 (45.6)	335 (43.0)	Risk ratio	1.06 (0.95 to 1.19)	0.31	1.05 (0.94 to 1.18)	0.39
			Risk difference	0.03 (-0.02 to 0.08)	0.31	0.02 (-0.01 to 0.06)	0.22
			Odds ratio	1.11 (0.91 to 1.36)	0.31	1.09 (0.95 to 1.26)	0.22
mRS score of 0 to 1 at 90 days, No. (%)	207 (27.2)	215 (27.6)	Risk ratio	0.99 (0.84 to 1.16)	0.86	0.97 (0.83 to 1.15)	0.74
			Risk difference	0 (-0.05 to 0.04)	0.86	-0.01 (-0.04 to 0.02)	0.64
			Odds ratio	0.98 (0.78 to 1.23)	0.86	0.96 (0.82 to 1.13)	0.64
NIHSS score at 5-7 days or earlier if discharge, median (IQR) [d]	10.0 (3.0, 21.5)	11.0 (4.0, 26.0)	Win Ratio	1.10 (0.97 to 1.24)	0.13	1.09 (0.97 to 1.23)	0.14
EQ-5D-VAS score at 90 days, median (IQR) [e]	55.0 (5.0, 85.0)	50.0 (0.0, 80.0)	Win Ratio	1.13 (1.00 to 1.28)	0.056	1.11 (0.98 to 1.26)	0.11

Abbreviations: mRS, modified Rankin scale; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; an EQ-5D-VAS, EuroQol-5 VAS score.

[a] The widths of the confidence intervals for the secondary outcomes were not adjusted for multiple comparisons, and the reported confidence intervals should not be used for hypothesis testing.

[b] The modified Rankin Scale of functional disability ranges from 0 (no symptoms) to 6 (death). Win proportion was calculated by the number of wins in Methylprednisolone group overPlacebo group in mRS among all possible pairs of mRS taking one patient from the Methylprednisolone group and one patient from the Placebo group divided by the total number of pairs.

[c] The GenOR indicated the probability of modified Rankin Scale score was lower than the other group. Generalized Odds Ratio, common odds ratio, risk ratio, and risk difference were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method and were not adjusted for multiple comparisons.

[d] Scores on the NIHSS range from 0 to 42, with higher values reflecting more severe neurologic impairment.

[e] The EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) visual-analogue scale is a continuous scale measure of self-reported quality of life. Scores range from 0 to 100, with 0 indicating the worst possible quality of life and 100 the best possible quality of life.

eTable 4. Primary Efficacy Outcomes—Sensitivity Analysis

Primary efficacy outcome	Treatment Effect	Adjusted Effect Size (95% CI)
Full Analysis Set		
mRS score at 90 days[a]		
Worst-case scenario[b]	GenOR	1.10 (0.96 - 1.25)
Best-case scenario[c]	GenOR	1.10 (0.96 - 1.25)
Multiple imputation[d]	GenOR	1.09 (0.96 - 1.25)
Mixed-effect model[e]	Common OR	1.15 (0.97 to 1.37)
Worst-best scenario (post-hoc)[f]	GenOR	1.08 (0.95 - 1.23)

Abbreviations: mRS, modified Rankin scale;

[a] The modified Rankin Scale of functional disability ranges from 0 (no symptoms) to 6 (death). Generalized odds ratios were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method, and common odds ratio was adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS, use of intravenous thrombolysis, time from onset to randomization, and occlusion location.

[b] Worst-case scenario imputed all patients with a missing primary endpoint and considered as the worst status (mRS = 6) in both treatment groups.

[c] Best-case scenario imputed all patients with a missing primary endpoint and considered as a success mRS 0 in both treatment groups.

[d] Missing mRS score were imputed using multiple imputation methods via SAS PROC MI. Imputation procedure will be performed under the missing-at-random (MAR) assumption. Fully conditional method (FCS) was used to predict missing mRS score by fitting an ordered logistic regression model with following predictors: treatment group, age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location, and last observed NIHSS if available. The seed was 128. A total of 10 imputed datasets were generated. GenOR was estimated for each dataset separately, and the pooled together to calculate the final pooled genOR and 95% confidence interval using the Robin's role.

[e] A proportional odds model with random effect will be fitted to estimate the common odds ratio between the methylprednisolone sodium succinate and placebo treatment with treatment as fixed effect, age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location as covariates, and the centre as a random effect

[f] Post-hoc worst-best scenario analysis: Patients with a missing primary endpoint in the placebo group was considered as a mRS of 0 while patients with a missing primary outcome in the methylprednisolone group was considered a mRS of 6.

eTable 5. Summary of Adverse Events (Safety Population).

Adverse Event	Methylprednisolone (N=839)	Placebo (N=841)	P-Value[a]
New Hyperglycemia	320 (38.1)	288 (34.2)	0.10
Hypernatremia	94 (11.2%)	116 (13.8)	0.11
New Diabetes	40 (4.8)	24 (2.9)	0.04
Hyperosmolar Hyperglycemic Syndrome	2 (0.2)	4 (0.5)	0.41
Insulin Use in Hospital Stay	165 (19.7)	110 (13.1)	0.0003
Craniectomy	40 (4.8)	45 (5.4)	0.59
Respiration Failure	200 (23.8)	226 (26.9)	0.15
Circulation Failure	114 (13.6)	158 (18.8)	0.004
Urinary tract infection	53 (6.32)	56 (6.66)	0.78
Other Infection	20 (2.38)	16 (1.90)	0.50
Deep Vein Thrombosis	42 (5.0)	44 (5.2)	0.83
Puncture site complication			0.39
Puncture site hematoma	4 (0.5)	9 (1.1)	
Pseudoaneurysm	9 (1.1)	10 (1.2)	
Embolism in other locations	0 (0)	1 (0.1)	

[a] post-hoc Chi-square/Fisher exact tests.

eTable 6 Summary of main outcome by participating centers.

	Center Order 1		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	1 (25.0%)	0 (0.0%)	1 (12.5%)
1	1 (25.0%)	0 (0.0%)	1 (12.5%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	1 (25.0%)	1 (12.5%)
4	0 (0.0%)	2 (50.0%)	2 (25.0%)
5	2 (50.0%)	0 (0.0%)	2 (25.0%)
6	0 (0.0%)	1 (25.0%)	1 (12.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	0 (0.0%)	2 (50.0%)	2 (25.0%)
Yes	4 (100.0%)	2 (50.0%)	6 (75.0%)
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%)
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%)
Puncture site hematomancture site complication,n (%)			

Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Craniectomy,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Respiration Failure,n (%)			
No	1 (25.0%)	1 (25.0%)	2 (25.0%)
Yes	3 (75.0%)	3 (75.0%)	6 (75.0%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

[1]Chi-Square p-value;

	Center Order 2		
	Group		
	Methylprednisolone (N=12)	Placebo (N=12)	Total (N=24)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	3 (25.0%)	1 (8.3%)	4 (16.7%)
2	1 (8.3%)	4 (33.3%)	5 (20.8%)
3	1 (8.3%)	1 (8.3%)	2 (8.3%)
4	2 (16.7%)	3 (25.0%)	5 (20.8%)
5	1 (8.3%)	0 (0.0%)	1 (4.2%)
6	4 (33.3%)	3 (25.0%)	7 (29.2%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	10 (90.9%)	11 (91.7%)	21 (91.3%)
Yes	1 (9.1%)	1 (8.3%)	2 (8.7%)
Missing	1	0	1

Pneumonia,n (%)			
No	7 (58.3%)	5 (41.7%)	12 (50.0%)
Yes	5 (41.7%)	7 (58.3%)	12 (50.0%)
Urinary tract infection,n (%)			
No	11 (91.7%)	12 (100.0%)	23 (95.8%)
Yes	1 (8.3%)	0 (0.0%)	1 (4.2%)
Other Infection,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	7 (58.3%)	12 (100.0%)	19 (79.2%)
Yes	5 (41.7%)	0 (0.0%)	5 (20.8%)
Craniectomy,n (%)			
No	10 (83.3%)	12 (100.0%)	22 (91.7%)
Yes	2 (16.7%)	0 (0.0%)	2 (8.3%)
Respiration Failure,n (%)			
No	8 (66.7%)	11 (91.7%)	19 (79.2%)
Yes	4 (33.3%)	1 (8.3%)	5 (20.8%)
Circulation Failure, n (%)			
No	10 (83.3%)	12 (100.0%)	22 (91.7%)
Yes	2 (16.7%)	0 (0.0%)	2 (8.3%)

[1]Chi-Square p-value;

	Center Order
	3

	Group		
	Methylprednisolone (N=8)	Placebo (N=8)	Total (N=16)
modified Rankin Scale score at 90 days,n (%)			
0	1 (12.5%)	1 (12.5%)	2 (12.5%)
1	0 (0.0%)	2 (25.0%)	2 (12.5%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	2 (25.0%)	1 (12.5%)	3 (18.8%)
4	3 (37.5%)	0 (0.0%)	3 (18.8%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (25.0%)	4 (50.0%)	6 (37.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	8 (100.0%)	6 (75.0%)	14 (87.5%)
Yes	0 (0.0%)	2 (25.0%)	2 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (37.5%)	5 (62.5%)	8 (50.0%)
Yes	5 (62.5%)	3 (37.5%)	8 (50.0%)
Urinary tract infection,n (%)			
No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			

No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	8 (100.0%)	6 (75.0%)	14 (87.5%)
Yes	0 (0.0%)	2 (25.0%)	2 (12.5%)
Respiration Failure,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Circulation Failure, n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)

[1]Chi-Square p-value;

	Center Order 4		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	2 (50.0%)	1 (25.0%)	3 (37.5%)
2	1 (25.0%)	0 (0.0%)	1 (12.5%)
3	1 (25.0%)	1 (25.0%)	2 (25.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	1 (25.0%)	1 (12.5%)
6	0 (0.0%)	1 (25.0%)	1 (12.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (100.0%)	2 (50.0%)	6 (75.0%)
Yes	0 (0.0%)	2 (50.0%)	2 (25.0%)
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)

Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

[1]Chi-Square p-value;

	Center Order 5		
	Group		
	Methylprednisolone (N=7)	Placebo (N=5)	Total (N=12)
modified Rankin Scale score at 90 days,n (%)			
0	1 (14.3%)	0 (0.0%)	1 (8.3%)

1	0 (0.0%)	2 (40.0%)	2 (16.7%)
2	2 (28.6%)	1 (20.0%)	3 (25.0%)
3	0 (0.0%)	1 (20.0%)	1 (8.3%)
4	1 (14.3%)	0 (0.0%)	1 (8.3%)
5	1 (14.3%)	0 (0.0%)	1 (8.3%)
6	2 (28.6%)	1 (20.0%)	3 (25.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	6 (85.7%)	4 (80.0%)	10 (83.3%)
Yes	1 (14.3%)	1 (20.0%)	2 (16.7%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (42.9%)	2 (40.0%)	5 (41.7%)
Yes	4 (57.1%)	3 (60.0%)	7 (58.3%)
Urinary tract infection,n (%)			
No	7 (100.0%)	5 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	7 (100.0%)	5 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	7 (100.0%)	5 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	7 (100.0%)	4 (80.0%)	11 (91.7%)
Pseudoaneurysm	0 (0.0%)	1 (20.0%)	1 (8.3%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	7 (100.0%)	5 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	6 (85.7%)	5 (100.0%)	11 (91.7%)
Yes	1 (14.3%)	0 (0.0%)	1 (8.3%)

Respiration Failure,n (%)			
No	5 (71.4%)	4 (80.0%)	9 (75.0%)
Yes	2 (28.6%)	1 (20.0%)	3 (25.0%)
Circulation Failure, n (%)			
No	7 (100.0%)	4 (80.0%)	11 (91.7%)
Yes	0 (0.0%)	1 (20.0%)	1 (8.3%)

[1]Chi-Square p-value;

	Center Order 6		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (25.0%)	1 (12.5%)
2	1 (25.0%)	1 (25.0%)	2 (25.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (75.0%)	2 (50.0%)	5 (62.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	1	0	1
Pneumonia,n (%)			
No	1 (25.0%)	2 (50.0%)	3 (37.5%)
Yes	3 (75.0%)	2 (50.0%)	5 (62.5%)
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%)
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%)
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%)
Circulation Failure, n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%)
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%)

[1]Chi-Square p-value;

	Center Order 8		
	Group		
	Methylprednisolone (N=16)	Placebo (N=16)	Total (N=32)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (12.5%)	2 (6.3%)
1	2 (12.5%)	1 (6.3%)	3 (9.4%)
2	4 (25.0%)	4 (25.0%)	8 (25.0%)
3	1 (6.3%)	5 (31.3%)	6 (18.8%)
4	1 (6.3%)	1 (6.3%)	2 (6.3%)
5	3 (18.8%)	0 (0.0%)	3 (9.4%)
6	5 (31.3%)	3 (18.8%)	8 (25.0%)

Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	15 (93.8%)	14 (87.5%)	29 (90.6%)
Yes	1 (6.3%)	2 (12.5%)	3 (9.4%)
Missing	0	0	0
Pneumonia,n (%)			
No	5 (31.3%)	3 (18.8%)	8 (25.0%)
Yes	11 (68.8%)	13 (81.3%)	24 (75.0%)
Urinary tract infection,n (%)			
No	14 (87.5%)	15 (93.8%)	29 (90.6%)
Yes	2 (12.5%)	1 (6.3%)	3 (9.4%)
Other Infection,n (%)			
No	16 (100.0%)	16 (100.0%)	32 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	14 (87.5%)	15 (93.8%)	29 (90.6%)
Yes	2 (12.5%)	1 (6.3%)	3 (9.4%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	16 (100.0%)	15 (93.8%)	31 (96.9%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	1 (6.3%)	1 (3.1%)
Insulin Use in Hospital Stay,n (%)			
No	11 (68.8%)	14 (87.5%)	25 (78.1%)
Yes	5 (31.3%)	2 (12.5%)	7 (21.9%)
Craniectomy,n (%)			
No	16 (100.0%)	16 (100.0%)	32 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	10 (62.5%)	15 (93.8%)	25 (78.1%)
Yes	6 (37.5%)	1 (6.3%)	7 (21.9%)
Circulation Failure, n (%)			

No	14 (87.5%)	15 (93.8%)	29 (90.6%)
Yes	2 (12.5%)	1 (6.3%)	3 (9.4%)

[1]Chi-Square p-value;

	Center Order 9		
	Group		
	Methylprednisolone (N=8)	Placebo (N=8)	Total (N=16)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	3 (37.5%)	0 (0.0%)	3 (18.8%)
2	1 (12.5%)	1 (12.5%)	2 (12.5%)
3	2 (25.0%)	0 (0.0%)	2 (12.5%)
4	2 (25.0%)	1 (12.5%)	3 (18.8%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	0 (0.0%)	6 (75.0%)	6 (37.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	8 (100.0%)	6 (75.0%)	14 (87.5%)
Yes	0 (0.0%)	2 (25.0%)	2 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (37.5%)	0 (0.0%)	3 (18.8%)
Yes	5 (62.5%)	8 (100.0%)	13 (81.3%)
Urinary tract infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	6 (75.0%)	7 (87.5%)	13 (81.3%)
Yes	2 (25.0%)	1 (12.5%)	3 (18.8%)
Craniectomy,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	5 (62.5%)	1 (12.5%)	6 (37.5%)
Yes	3 (37.5%)	7 (87.5%)	10 (62.5%)
Circulation Failure, n (%)			
No	8 (100.0%)	6 (75.0%)	14 (87.5%)
Yes	0 (0.0%)	2 (25.0%)	2 (12.5%)

[1]Chi-Square p-value;

	Center Order 10		
	Group		
	Methylprednisolone (N=18)	Placebo (N=16)	Total (N=34)
modified Rankin Scale score at 90 days,n (%)			
0	2 (11.1%)	2 (12.5%)	4 (11.8%)
1	3 (16.7%)	6 (37.5%)	9 (26.5%)
2	3 (16.7%)	5 (31.3%)	8 (23.5%)
3	3 (16.7%)	0 (0.0%)	3 (8.8%)
4	3 (16.7%)	2 (12.5%)	5 (14.7%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	4 (22.2%)	1 (6.3%)	5 (14.7%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	17 (94.4%)	16 (100.0%)	33 (97.1%)
Yes	1 (5.6%)	0 (0.0%)	1 (2.9%)

Missing	0	0	0
Pneumonia,n (%)			
No	11 (61.1%)	12 (75.0%)	23 (67.6%)
Yes	7 (38.9%)	4 (25.0%)	11 (32.4%)
Urinary tract infection,n (%)			
No	17 (94.4%)	14 (87.5%)	31 (91.2%)
Yes	1 (5.6%)	2 (12.5%)	3 (8.8%)
Other Infection,n (%)			
No	17 (94.4%)	16 (100.0%)	33 (97.1%)
Yes	1 (5.6%)	0 (0.0%)	1 (2.9%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	17 (94.4%)	16 (100.0%)	33 (97.1%)
Yes	1 (5.6%)	0 (0.0%)	1 (2.9%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	18 (100.0%)	16 (100.0%)	34 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	13 (72.2%)	14 (87.5%)	27 (79.4%)
Yes	5 (27.8%)	2 (12.5%)	7 (20.6%)
Craniectomy,n (%)			
No	17 (94.4%)	16 (100.0%)	33 (97.1%)
Yes	1 (5.6%)	0 (0.0%)	1 (2.9%)
Respiration Failure,n (%)			
No	16 (88.9%)	15 (93.8%)	31 (91.2%)
Yes	2 (11.1%)	1 (6.3%)	3 (8.8%)
Circulation Failure, n (%)			
No	16 (88.9%)	13 (81.3%)	29 (85.3%)
Yes	2 (11.1%)	3 (18.8%)	5 (14.7%)

[1]Chi-Square p-value;

	Center Order 11		
	Group		
	Methylprednisolone (N=19)	Placebo (N=17)	Total (N=36)
modified Rankin Scale score at 90 days,n (%)			
0	2 (10.5%)	3 (17.6%)	5 (13.9%)
1	5 (26.3%)	4 (23.5%)	9 (25.0%)
2	0 (0.0%)	2 (11.8%)	2 (5.6%)
3	6 (31.6%)	2 (11.8%)	8 (22.2%)
4	3 (15.8%)	2 (11.8%)	5 (13.9%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (15.8%)	4 (23.5%)	7 (19.4%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	17 (89.5%)	14 (82.4%)	31 (86.1%)
Yes	2 (10.5%)	3 (17.6%)	5 (13.9%)
Missing	0	0	0
Pneumonia,n (%)			
No	10 (52.6%)	7 (41.2%)	17 (47.2%)
Yes	9 (47.4%)	10 (58.8%)	19 (52.8%)
Urinary tract infection,n (%)			
No	18 (94.7%)	17 (100.0%)	35 (97.2%)
Yes	1 (5.3%)	0 (0.0%)	1 (2.8%)
Other Infection,n (%)			
No	19 (100.0%)	17 (100.0%)	36 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	19 (100.0%)	15 (88.2%)	34 (94.4%)
Yes	0 (0.0%)	2 (11.8%)	2 (5.6%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	19 (100.0%)	17 (100.0%)	36 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)

Insulin Use in Hospital Stay,n (%)			
No	11 (57.9%)	13 (76.5%)	24 (66.7%)
Yes	8 (42.1%)	4 (23.5%)	12 (33.3%)
Craniectomy,n (%)			
No	17 (89.5%)	13 (76.5%)	30 (83.3%)
Yes	2 (10.5%)	4 (23.5%)	6 (16.7%)
Respiration Failure,n (%)			
No	13 (68.4%)	11 (64.7%)	24 (66.7%)
Yes	6 (31.6%)	6 (35.3%)	12 (33.3%)
Circulation Failure, n (%)			
No	16 (84.2%)	11 (64.7%)	27 (75.0%)
Yes	3 (15.8%)	6 (35.3%)	9 (25.0%)

[1]Chi-Square p-value;

	Center Order 12		
	Group		
	Methylprednisolone (N=4)	Placebo (N=6)	Total (N=10)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (25.0%)	1 (16.7%)	2 (20.0%)
2	2 (50.0%)	0 (0.0%)	2 (20.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (25.0%)	5 (83.3%)	6 (60.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	2 (40.0%)	6 (66.7%)
Yes	0 (0.0%)	3 (60.0%)	3 (33.3%)
Missing	0	1	1
Pneumonia,n (%)			
No	4 (100.0%)	2 (33.3%)	6 (60.0%)
Yes	0 (0.0%)	4 (66.7%)	4 (40.0%)

Urinary tract infection,n (%)			
No	4 (100.0%)	6 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	6 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	5 (83.3%)	9 (90.0%)
Yes	0 (0.0%)	1 (16.7%)	1 (10.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	6 (100.0%)	10 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	4 (66.7%)	8 (80.0%)
Yes	0 (0.0%)	2 (33.3%)	2 (20.0%)
Craniectomy,n (%)			
No	4 (100.0%)	6 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	3 (75.0%)	1 (16.7%)	4 (40.0%)
Yes	1 (25.0%)	5 (83.3%)	6 (60.0%)
Circulation Failure, n (%)			
No	3 (75.0%)	6 (100.0%)	9 (90.0%)
Yes	1 (25.0%)	0 (0.0%)	1 (10.0%)

[1]Chi-Square p-value;

	Center Order 13		
	Group		
	Methylprednisolone (N=3)	Placebo (N=2)	Total (N=5)

modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	2 (66.7%)	0 (0.0%)	2 (40.0%)
3	0 (0.0%)	1 (50.0%)	1 (20.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (33.3%)	1 (50.0%)	2 (40.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	2 (66.7%)	0 (0.0%)	2 (40.0%)
Yes	1 (33.3%)	2 (100.0%)	3 (60.0%)
Urinary tract infection,n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (66.7%)	1 (50.0%)	3 (60.0%)
Yes	1 (33.3%)	1 (50.0%)	2 (40.0%)

Craniectomy,n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	3 (100.0%)	1 (50.0%)	4 (80.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (20.0%)
Circulation Failure, n (%)			
No	3 (100.0%)	1 (50.0%)	4 (80.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (20.0%)

[1]Chi-Square p-value;

	Center Order 14		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (25.0%)	1 (12.5%)
1	1 (25.0%)	0 (0.0%)	1 (12.5%)
2	1 (25.0%)	2 (50.0%)	3 (37.5%)
3	1 (25.0%)	1 (25.0%)	2 (25.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	1 (25.0%)	3 (75.0%)	4 (50.0%)
Yes	3 (75.0%)	1 (25.0%)	4 (50.0%)
Urinary tract infection,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%)
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)
Other Infection,n (%)			

No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Circulation Failure, n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

[1]Chi-Square p-value;

	Center Order 15		
	Group		
	Methylprednisolone (N=16)	Placebo (N=16)	Total (N=32)
modified Rankin Scale score at 90 days,n (%)			
0	2 (12.5%)	3 (18.8%)	5 (15.6%)
1	1 (6.3%)	2 (12.5%)	3 (9.4%)
2	3 (18.8%)	1 (6.3%)	4 (12.5%)
3	2 (12.5%)	3 (18.8%)	5 (15.6%)

4	3 (18.8%)	4 (25.0%)	7 (21.9%)
5	2 (12.5%)	1 (6.3%)	3 (9.4%)
6	3 (18.8%)	2 (12.5%)	5 (15.6%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	15 (93.8%)	16 (100.0%)	31 (96.9%)
Yes	1 (6.3%)	0 (0.0%)	1 (3.1%)
Missing	0	0	0
Pneumonia,n (%)			
No	9 (56.3%)	7 (43.8%)	16 (50.0%)
Yes	7 (43.8%)	9 (56.3%)	16 (50.0%)
Urinary tract infection,n (%)			
No	16 (100.0%)	14 (87.5%)	30 (93.8%)
Yes	0 (0.0%)	2 (12.5%)	2 (6.3%)
Other Infection,n (%)			
No	16 (100.0%)	15 (93.8%)	31 (96.9%)
Yes	0 (0.0%)	1 (6.3%)	1 (3.1%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	16 (100.0%)	15 (93.8%)	31 (96.9%)
Yes	0 (0.0%)	1 (6.3%)	1 (3.1%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	16 (100.0%)	16 (100.0%)	32 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	12 (75.0%)	13 (81.3%)	25 (78.1%)
Yes	4 (25.0%)	3 (18.8%)	7 (21.9%)
Craniectomy,n (%)			
No	16 (100.0%)	14 (87.5%)	30 (93.8%)
Yes	0 (0.0%)	2 (12.5%)	2 (6.3%)
Respiration Failure,n (%)			
No	15 (93.8%)	11 (68.8%)	26 (81.3%)

Yes	1 (6.3%)	5 (31.3%)	6 (18.8%)
Circulation Failure, n (%)			
No	15 (93.8%)	14 (87.5%)	29 (90.6%)
Yes	1 (6.3%)	2 (12.5%)	3 (9.4%)

[1]Chi-Square p-value;

	Center Order		
	17		
	Group		
	Methylprednisolone (N=21)	Placebo (N=20)	Total (N=41)
modified Rankin Scale score at 90 days,n (%)			
0	1 (4.8%)	2 (10.0%)	3 (7.3%)
1	3 (14.3%)	4 (20.0%)	7 (17.1%)
2	4 (19.0%)	5 (25.0%)	9 (22.0%)
3	1 (4.8%)	2 (10.0%)	3 (7.3%)
4	3 (14.3%)	0 (0.0%)	3 (7.3%)
5	0 (0.0%)	2 (10.0%)	2 (4.9%)
6	9 (42.9%)	5 (25.0%)	14 (34.1%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	18 (90.0%)	19 (95.0%)	37 (92.5%)
Yes	2 (10.0%)	1 (5.0%)	3 (7.5%)
Missing	1	0	1
Pneumonia,n (%)			
No	15 (71.4%)	10 (50.0%)	25 (61.0%)
Yes	6 (28.6%)	10 (50.0%)	16 (39.0%)
Urinary tract infection,n (%)			
No	19 (90.5%)	18 (90.0%)	37 (90.2%)
Yes	2 (9.5%)	2 (10.0%)	4 (9.8%)
Other Infection,n (%)			
No	21 (100.0%)	20 (100.0%)	41 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	21 (100.0%)	19 (95.0%)	40 (97.6%)

Yes	0 (0.0%)	1 (5.0%)	1 (2.4%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	21 (100.0%)	20 (100.0%)	41 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	17 (81.0%)	20 (100.0%)	37 (90.2%)
Yes	4 (19.0%)	0 (0.0%)	4 (9.8%)
Craniectomy,n (%)			
No	20 (95.2%)	20 (100.0%)	40 (97.6%)
Yes	1 (4.8%)	0 (0.0%)	1 (2.4%)
Respiration Failure,n (%)			
No	16 (76.2%)	17 (85.0%)	33 (80.5%)
Yes	5 (23.8%)	3 (15.0%)	8 (19.5%)
Circulation Failure, n (%)			
No	16 (76.2%)	15 (75.0%)	31 (75.6%)
Yes	5 (23.8%)	5 (25.0%)	10 (24.4%)

[1]Chi-Square p-value;

	Center Order 18		
	Group		
	Methylprednisolone (N=15)	Placebo (N=15)	Total (N=30)
modified Rankin Scale score at 90 days,n (%)			
0	2 (14.3%)	1 (6.7%)	3 (10.3%)
1	3 (21.4%)	4 (26.7%)	7 (24.1%)
2	6 (42.9%)	2 (13.3%)	8 (27.6%)
3	1 (7.1%)	4 (26.7%)	5 (17.2%)
4	1 (7.1%)	1 (6.7%)	2 (6.9%)
5	0 (0.0%)	1 (6.7%)	1 (3.4%)
6	1 (7.1%)	2 (13.3%)	3 (10.3%)
Missing	1	0	1
Symptomatic intracranial hemorrhage, n (%)			

No	14 (93.3%)	14 (93.3%)	28 (93.3%)
Yes	1 (6.7%)	1 (6.7%)	2 (6.7%)
Missing	0	0	0
Pneumonia,n (%)			
No	10 (66.7%)	9 (60.0%)	19 (63.3%)
Yes	5 (33.3%)	6 (40.0%)	11 (36.7%)
Urinary tract infection,n (%)			
No	15 (100.0%)	14 (93.3%)	29 (96.7%)
Yes	0 (0.0%)	1 (6.7%)	1 (3.3%)
Other Infection,n (%)			
No	15 (100.0%)	15 (100.0%)	30 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	15 (100.0%)	13 (86.7%)	28 (93.3%)
Yes	0 (0.0%)	2 (13.3%)	2 (6.7%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	15 (100.0%)	14 (93.3%)	29 (96.7%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	1 (6.7%)	1 (3.3%)
Insulin Use in Hospital Stay,n (%)			
No	14 (93.3%)	15 (100.0%)	29 (96.7%)
Yes	1 (6.7%)	0 (0.0%)	1 (3.3%)
Craniectomy,n (%)			
No	15 (100.0%)	14 (93.3%)	29 (96.7%)
Yes	0 (0.0%)	1 (6.7%)	1 (3.3%)
Respiration Failure,n (%)			
No	15 (100.0%)	13 (86.7%)	28 (93.3%)
Yes	0 (0.0%)	2 (13.3%)	2 (6.7%)
Circulation Failure, n (%)			
No	15 (100.0%)	15 (100.0%)	30 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

[1]Chi-Square p-value;

	Center Order		
	20		
	Group		
	Methylprednisolone (N=22)	Placebo (N=22)	Total (N=44)
modified Rankin Scale score at 90 days,n (%)			
0	1 (4.5%)	3 (14.3%)	4 (9.3%)
1	5 (22.7%)	3 (14.3%)	8 (18.6%)
2	3 (13.6%)	3 (14.3%)	6 (14.0%)
3	3 (13.6%)	1 (4.8%)	4 (9.3%)
4	1 (4.5%)	0 (0.0%)	1 (2.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	9 (40.9%)	11 (52.4%)	20 (46.5%)
Missing	0	1	1
Symptomatic intracranial hemorrhage, n (%)			
No	19 (86.4%)	20 (100.0%)	39 (92.9%)
Yes	3 (13.6%)	0 (0.0%)	3 (7.1%)
Missing	0	2	2
Pneumonia,n (%)			
No	11 (50.0%)	8 (36.4%)	19 (43.2%)
Yes	11 (50.0%)	14 (63.6%)	25 (56.8%)
Urinary tract infection,n (%)			
No	18 (81.8%)	20 (90.9%)	38 (86.4%)
Yes	4 (18.2%)	2 (9.1%)	6 (13.6%)
Other Infection,n (%)			
No	22 (100.0%)	22 (100.0%)	44 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	21 (95.5%)	22 (100.0%)	43 (97.7%)
Yes	1 (4.5%)	0 (0.0%)	1 (2.3%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	21 (95.5%)	22 (100.0%)	43 (97.7%)

Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	1 (4.5%)	0 (0.0%)	1 (2.3%)
Insulin Use in Hospital Stay,n (%)			
No	19 (86.4%)	18 (81.8%)	37 (84.1%)
Yes	3 (13.6%)	4 (18.2%)	7 (15.9%)
Craniectomy,n (%)			
No	20 (90.9%)	20 (90.9%)	40 (90.9%)
Yes	2 (9.1%)	2 (9.1%)	4 (9.1%)
Respiration Failure,n (%)			
No	16 (72.7%)	16 (72.7%)	32 (72.7%)
Yes	6 (27.3%)	6 (27.3%)	12 (27.3%)
Circulation Failure, n (%)			
No	18 (81.8%)	16 (72.7%)	34 (77.3%)
Yes	4 (18.2%)	6 (27.3%)	10 (22.7%)

[1]Chi-Square p-value;

	Center Order		
	22		
	Group		
	Methylprednisolone	Placebo	Total
	(N=6)	(N=8)	(N=14)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (25.0%)	2 (14.3%)
1	2 (33.3%)	1 (12.5%)	3 (21.4%)
2	1 (16.7%)	2 (25.0%)	3 (21.4%)
3	1 (16.7%)	0 (0.0%)	1 (7.1%)
4	1 (16.7%)	1 (12.5%)	2 (14.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (16.7%)	2 (25.0%)	3 (21.4%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	6 (100.0%)	7 (87.5%)	13 (92.9%)
Yes	0 (0.0%)	1 (12.5%)	1 (7.1%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (66.7%)	5 (62.5%)	9 (64.3%)

Yes	2 (33.3%)	3 (37.5%)	5 (35.7%)
Urinary tract infection,n (%)			
No	6 (100.0%)	8 (100.0%)	14 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	6 (100.0%)	8 (100.0%)	14 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	6 (100.0%)	8 (100.0%)	14 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	6 (100.0%)	8 (100.0%)	14 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	5 (83.3%)	8 (100.0%)	13 (92.9%)
Yes	1 (16.7%)	0 (0.0%)	1 (7.1%)
Craniectomy,n (%)			
No	6 (100.0%)	8 (100.0%)	14 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (66.7%)	7 (87.5%)	11 (78.6%)
Yes	2 (33.3%)	1 (12.5%)	3 (21.4%)
Circulation Failure, n (%)			
No	5 (83.3%)	6 (75.0%)	11 (78.6%)
Yes	1 (16.7%)	2 (25.0%)	3 (21.4%)

[1]Chi-Square p-value;

	Center Order		
	23		
	Group		
	Methylprednisolone	Placebo	Total

	(N=24)	(N=22)	(N=46)
modified Rankin Scale score at 90 days,n (%)			
0	5 (20.8%)	4 (18.2%)	9 (19.6%)
1	6 (25.0%)	5 (22.7%)	11 (23.9%)
2	5 (20.8%)	1 (4.5%)	6 (13.0%)
3	2 (8.3%)	1 (4.5%)	3 (6.5%)
4	3 (12.5%)	2 (9.1%)	5 (10.9%)
5	1 (4.2%)	2 (9.1%)	3 (6.5%)
6	2 (8.3%)	7 (31.8%)	9 (19.6%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	22 (91.7%)	19 (86.4%)	41 (89.1%)
Yes	2 (8.3%)	3 (13.6%)	5 (10.9%)
Missing	0	0	0
Pneumonia,n (%)			
No	19 (79.2%)	16 (72.7%)	35 (76.1%)
Yes	5 (20.8%)	6 (27.3%)	11 (23.9%)
Urinary tract infection,n (%)			
No	22 (91.7%)	21 (95.5%)	43 (93.5%)
Yes	2 (8.3%)	1 (4.5%)	3 (6.5%)
Other Infection,n (%)			
No	24 (100.0%)	21 (95.5%)	45 (97.8%)
Yes	0 (0.0%)	1 (4.5%)	1 (2.2%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	24 (100.0%)	22 (100.0%)	46 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	24 (100.0%)	20 (90.9%)	44 (95.7%)
Pseudoaneurysm	0 (0.0%)	1 (4.5%)	1 (2.2%)
Puncture site hematoma	0 (0.0%)	1 (4.5%)	1 (2.2%)
Insulin Use in Hospital Stay,n (%)			
No	21 (87.5%)	19 (86.4%)	40 (87.0%)
Yes	3 (12.5%)	3 (13.6%)	6 (13.0%)

Craniectomy,n (%)			
No	24 (100.0%)	21 (95.5%)	45 (97.8%)
Yes	0 (0.0%)	1 (4.5%)	1 (2.2%)
Respiration Failure,n (%)			
No	20 (83.3%)	17 (77.3%)	37 (80.4%)
Yes	4 (16.7%)	5 (22.7%)	9 (19.6%)
Circulation Failure, n (%)			
No	23 (95.8%)	20 (90.9%)	43 (93.5%)
Yes	1 (4.2%)	2 (9.1%)	3 (6.5%)

[1]Chi-Square p-value;

	Center Order		
	24		
	Group		
	Methylprednisolone (N=11)	Placebo (N=11)	Total (N=22)
modified Rankin Scale score at 90 days,n (%)			
0	1 (9.1%)	0 (0.0%)	1 (4.5%)
1	1 (9.1%)	3 (27.3%)	4 (18.2%)
2	4 (36.4%)	2 (18.2%)	6 (27.3%)
3	2 (18.2%)	1 (9.1%)	3 (13.6%)
4	2 (18.2%)	1 (9.1%)	3 (13.6%)
5	1 (9.1%)	0 (0.0%)	1 (4.5%)
6	0 (0.0%)	4 (36.4%)	4 (18.2%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	11 (100.0%)	8 (72.7%)	19 (86.4%)
Yes	0 (0.0%)	3 (27.3%)	3 (13.6%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (36.4%)	5 (45.5%)	9 (40.9%)
Yes	7 (63.6%)	6 (54.5%)	13 (59.1%)
Urinary tract infection,n (%)			
No	8 (72.7%)	8 (72.7%)	16 (72.7%)
Yes	3 (27.3%)	3 (27.3%)	6 (27.3%)

Other Infection,n (%)			
No	11 (100.0%)	11 (100.0%)	22 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	10 (90.9%)	8 (72.7%)	18 (81.8%)
Yes	1 (9.1%)	3 (27.3%)	4 (18.2%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	11 (100.0%)	11 (100.0%)	22 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	9 (81.8%)	11 (100.0%)	20 (90.9%)
Yes	2 (18.2%)	0 (0.0%)	2 (9.1%)
Craniectomy,n (%)			
No	11 (100.0%)	10 (90.9%)	21 (95.5%)
Yes	0 (0.0%)	1 (9.1%)	1 (4.5%)
Respiration Failure,n (%)			
No	8 (72.7%)	7 (63.6%)	15 (68.2%)
Yes	3 (27.3%)	4 (36.4%)	7 (31.8%)
Circulation Failure, n (%)			
No	10 (90.9%)	7 (63.6%)	17 (77.3%)
Yes	1 (9.1%)	4 (36.4%)	5 (22.7%)

[1]Chi-Square p-value;

	Center Order 25		
	Group		
	Methylprednisolone (N=8)	Placebo (N=8)	Total (N=16)
modified Rankin Scale score at 90 days,n (%)			
0	1 (12.5%)	1 (12.5%)	2 (12.5%)
1	0 (0.0%)	3 (37.5%)	3 (18.8%)
2	1 (12.5%)	1 (12.5%)	2 (12.5%)

3	2 (25.0%)	0 (0.0%)	2 (12.5%)
4	2 (25.0%)	1 (12.5%)	3 (18.8%)
5	0 (0.0%)	1 (12.5%)	1 (6.3%)
6	2 (25.0%)	1 (12.5%)	3 (18.8%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (37.5%)	5 (62.5%)	8 (50.0%)
Yes	5 (62.5%)	3 (37.5%)	8 (50.0%)
Urinary tract infection,n (%)			
No	6 (75.0%)	8 (100.0%)	14 (87.5%)
Yes	2 (25.0%)	0 (0.0%)	2 (12.5%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	7 (87.5%)	6 (75.0%)	13 (81.3%)
Yes	1 (12.5%)	2 (25.0%)	3 (18.8%)
Craniectomy,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Respiration Failure,n (%)			

No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Circulation Failure, n (%)			
No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)

[1]Chi-Square p-value;

	Center Order 26		
	Group		
	Methylprednisolone (N=40)	Placebo (N=38)	Total (N=78)
modified Rankin Scale score at 90 days,n (%)			
0	8 (20.0%)	10 (26.3%)	18 (23.1%)
1	5 (12.5%)	11 (28.9%)	16 (20.5%)
2	8 (20.0%)	8 (21.1%)	16 (20.5%)
3	6 (15.0%)	4 (10.5%)	10 (12.8%)
4	6 (15.0%)	1 (2.6%)	7 (9.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	7 (17.5%)	4 (10.5%)	11 (14.1%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	37 (92.5%)	35 (94.6%)	72 (93.5%)
Yes	3 (7.5%)	2 (5.4%)	5 (6.5%)
Missing	0	1	1
Pneumonia,n (%)			
No	33 (82.5%)	25 (65.8%)	58 (74.4%)
Yes	7 (17.5%)	13 (34.2%)	20 (25.6%)
Urinary tract infection,n (%)			
No	40 (100.0%)	37 (97.4%)	77 (98.7%)
Yes	0 (0.0%)	1 (2.6%)	1 (1.3%)
Other Infection,n (%)			
No	40 (100.0%)	38 (100.0%)	78 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			

No	40 (100.0%)	38 (100.0%)	78 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	39 (97.5%)	35 (92.1%)	74 (94.9%)
Pseudoaneurysm	1 (2.5%)	3 (7.9%)	4 (5.1%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	38 (95.0%)	37 (97.4%)	75 (96.2%)
Yes	2 (5.0%)	1 (2.6%)	3 (3.8%)
Craniectomy,n (%)			
No	40 (100.0%)	38 (100.0%)	78 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	35 (87.5%)	33 (86.8%)	68 (87.2%)
Yes	5 (12.5%)	5 (13.2%)	10 (12.8%)
Circulation Failure, n (%)			
No	38 (95.0%)	31 (81.6%)	69 (88.5%)
Yes	2 (5.0%)	7 (18.4%)	9 (11.5%)

[1]Chi-Square p-value;

	Center Order 27		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	1 (25.0%)	0 (0.0%)	1 (12.5%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	1 (25.0%)	0 (0.0%)	1 (12.5%)
3	0 (0.0%)	1 (25.0%)	1 (12.5%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	1 (25.0%)	1 (12.5%)
6	2 (50.0%)	2 (50.0%)	4 (50.0%)
Missing	0	0	0

Symptomatic intracranial hemorrhage, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (75.0%)	2 (50.0%)	5 (62.5%)
Yes	1 (25.0%)	2 (50.0%)	3 (37.5%)
Urinary tract infection,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%)
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (50.0%)	2 (50.0%)	4 (50.0%)
Yes	2 (50.0%)	2 (50.0%)	4 (50.0%)
Circulation Failure, n (%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%)
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%)

[1]Chi-Square p-value;

	Center Order 28		
	Group		
	Methylprednisolone (N=10)	Placebo (N=10)	Total (N=20)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (20.0%)	2 (10.0%)
1	3 (30.0%)	1 (10.0%)	4 (20.0%)
2	2 (20.0%)	2 (20.0%)	4 (20.0%)
3	1 (10.0%)	4 (40.0%)	5 (25.0%)
4	1 (10.0%)	0 (0.0%)	1 (5.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (30.0%)	1 (10.0%)	4 (20.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	9 (100.0%)	9 (90.0%)	18 (94.7%)
Yes	0 (0.0%)	1 (10.0%)	1 (5.3%)
Missing	1	0	1
Pneumonia,n (%)			
No	5 (50.0%)	5 (50.0%)	10 (50.0%)
Yes	5 (50.0%)	5 (50.0%)	10 (50.0%)
Urinary tract infection,n (%)			
No	8 (80.0%)	10 (100.0%)	18 (90.0%)
Yes	2 (20.0%)	0 (0.0%)	2 (10.0%)
Other Infection,n (%)			
No	10 (100.0%)	9 (90.0%)	19 (95.0%)
Yes	0 (0.0%)	1 (10.0%)	1 (5.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	10 (100.0%)	9 (90.0%)	19 (95.0%)
Yes	0 (0.0%)	1 (10.0%)	1 (5.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)

No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	9 (90.0%)	9 (90.0%)	18 (90.0%)
Yes	1 (10.0%)	1 (10.0%)	2 (10.0%)
Craniectomy,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	7 (70.0%)	10 (100.0%)	17 (85.0%)
Yes	3 (30.0%)	0 (0.0%)	3 (15.0%)
Circulation Failure, n (%)			
No	8 (80.0%)	8 (80.0%)	16 (80.0%)
Yes	2 (20.0%)	2 (20.0%)	4 (20.0%)

[1]Chi-Square p-value;

	Center Order 29		
	Group		
	Methylprednisolone (N=63)	Placebo (N=63)	Total (N=126)
modified Rankin Scale score at 90 days,n (%)			
0	9 (14.3%)	4 (6.3%)	13 (10.3%)
1	15 (23.8%)	13 (20.6%)	28 (22.2%)
2	11 (17.5%)	11 (17.5%)	22 (17.5%)
3	6 (9.5%)	9 (14.3%)	15 (11.9%)
4	6 (9.5%)	7 (11.1%)	13 (10.3%)
5	5 (7.9%)	6 (9.5%)	11 (8.7%)
6	11 (17.5%)	13 (20.6%)	24 (19.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	57 (91.9%)	59 (95.2%)	116 (93.5%)
Yes	5 (8.1%)	3 (4.8%)	8 (6.5%)
Missing	1	1	2
Pneumonia,n (%)			

No	23 (36.5%)	17 (27.0%)	40 (31.7%)
Yes	40 (63.5%)	46 (73.0%)	86 (68.3%)
Urinary tract infection,n (%)			
No	60 (95.2%)	54 (85.7%)	114 (90.5%)
Yes	3 (4.8%)	9 (14.3%)	12 (9.5%)
Other Infection,n (%)			
No	60 (95.2%)	61 (96.8%)	121 (96.0%)
Yes	3 (4.8%)	2 (3.2%)	5 (4.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	60 (95.2%)	57 (90.5%)	117 (92.9%)
Yes	3 (4.8%)	6 (9.5%)	9 (7.1%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	63 (100.0%)	63 (100.0%)	126 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	49 (77.8%)	49 (77.8%)	98 (77.8%)
Yes	14 (22.2%)	14 (22.2%)	28 (22.2%)
Craniectomy,n (%)			
No	58 (92.1%)	57 (90.5%)	115 (91.3%)
Yes	5 (7.9%)	6 (9.5%)	11 (8.7%)
Respiration Failure,n (%)			
No	51 (81.0%)	44 (69.8%)	95 (75.4%)
Yes	12 (19.0%)	19 (30.2%)	31 (24.6%)
Circulation Failure, n (%)			
No	48 (76.2%)	47 (74.6%)	95 (75.4%)
Yes	15 (23.8%)	16 (25.4%)	31 (24.6%)

[1]Chi-Square p-value;

	Center Order
	32

	Group		
	Methylprednisolone (N=2)	Placebo (N=2)	Total (N=4)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (50.0%)	0 (0.0%)	1 (25.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	1 (50.0%)	1 (50.0%)	2 (50.0%)
4	0 (0.0%)	1 (50.0%)	1 (25.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	1 (50.0%)	0 (0.0%)	1 (25.0%)
Yes	1 (50.0%)	2 (100.0%)	3 (75.0%)
Urinary tract infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			

No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Craniectomy,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Circulation Failure, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

[1]Chi-Square p-value;

	Center Order 33		
	Group		
	Methylprednisolone (N=15)	Placebo (N=16)	Total (N=31)
modified Rankin Scale score at 90 days,n (%)			
0	1 (6.7%)	2 (12.5%)	3 (9.7%)
1	4 (26.7%)	1 (6.3%)	5 (16.1%)
2	3 (20.0%)	3 (18.8%)	6 (19.4%)
3	1 (6.7%)	2 (12.5%)	3 (9.7%)
4	2 (13.3%)	2 (12.5%)	4 (12.9%)
5	1 (6.7%)	0 (0.0%)	1 (3.2%)
6	3 (20.0%)	6 (37.5%)	9 (29.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	14 (93.3%)	13 (81.3%)	27 (87.1%)
Yes	1 (6.7%)	3 (18.8%)	4 (12.9%)
Missing	0	0	0
Pneumonia,n (%)			
No	10 (66.7%)	6 (37.5%)	16 (51.6%)
Yes	5 (33.3%)	10 (62.5%)	15 (48.4%)
Urinary tract infection,n (%)			
No	15 (100.0%)	16 (100.0%)	31 (100.0%)

Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	15 (100.0%)	16 (100.0%)	31 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	14 (93.3%)	15 (93.8%)	29 (93.5%)
Yes	1 (6.7%)	1 (6.3%)	2 (6.5%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	15 (100.0%)	16 (100.0%)	31 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	14 (93.3%)	12 (75.0%)	26 (83.9%)
Yes	1 (6.7%)	4 (25.0%)	5 (16.1%)
Craniectomy,n (%)			
No	15 (100.0%)	15 (93.8%)	30 (96.8%)
Yes	0 (0.0%)	1 (6.3%)	1 (3.2%)
Respiration Failure,n (%)			
No	15 (100.0%)	13 (81.3%)	28 (90.3%)
Yes	0 (0.0%)	3 (18.8%)	3 (9.7%)
Circulation Failure, n (%)			
No	14 (93.3%)	13 (81.3%)	27 (87.1%)
Yes	1 (6.7%)	3 (18.8%)	4 (12.9%)

[1]Chi-Square p-value;

	Center Order 34		
	Group		
	Methylprednisolone (N=17)	Placebo (N=16)	Total (N=33)
modified Rankin Scale score at 90 days,n (%)			
0	2 (11.8%)	0 (0.0%)	2 (6.3%)

1	1 (5.9%)	5 (33.3%)	6 (18.8%)
2	4 (23.5%)	1 (6.7%)	5 (15.6%)
3	4 (23.5%)	0 (0.0%)	4 (12.5%)
4	2 (11.8%)	4 (26.7%)	6 (18.8%)
5	1 (5.9%)	1 (6.7%)	2 (6.3%)
6	3 (17.6%)	4 (26.7%)	7 (21.9%)
Missing	0	1	1
Symptomatic intracranial hemorrhage, n (%)			
No	14 (82.4%)	15 (93.8%)	29 (87.9%)
Yes	3 (17.6%)	1 (6.3%)	4 (12.1%)
Missing	0	0	0
Pneumonia,n (%)			
No	9 (52.9%)	7 (43.8%)	16 (48.5%)
Yes	8 (47.1%)	9 (56.3%)	17 (51.5%)
Urinary tract infection,n (%)			
No	17 (100.0%)	16 (100.0%)	33 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	17 (100.0%)	16 (100.0%)	33 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	17 (100.0%)	16 (100.0%)	33 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	17 (100.0%)	16 (100.0%)	33 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	14 (82.4%)	16 (100.0%)	30 (90.9%)
Yes	3 (17.6%)	0 (0.0%)	3 (9.1%)
Craniectomy,n (%)			
No	15 (88.2%)	16 (100.0%)	31 (93.9%)
Yes	2 (11.8%)	0 (0.0%)	2 (6.1%)

Respiration Failure,n (%)			
No	13 (76.5%)	15 (93.8%)	28 (84.8%)
Yes	4 (23.5%)	1 (6.3%)	5 (15.2%)
Circulation Failure, n (%)			
No	12 (70.6%)	15 (93.8%)	27 (81.8%)
Yes	5 (29.4%)	1 (6.3%)	6 (18.2%)

[1]Chi-Square p-value;

	Center Order		
	35		
	Group		
	Methylprednisolone (N=2)	Placebo (N=2)	Total (N=4)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	1 (50.0%)	1 (50.0%)	2 (50.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (50.0%)	1 (50.0%)	2 (50.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	0 (0.0%)	0 (0.0%)	0 (0.0%)
Yes	2 (100.0%)	2 (100.0%)	4 (100.0%)
Urinary tract infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	1 (50.0%)	2 (100.0%)	3 (75.0%)
Yes	1 (50.0%)	0 (0.0%)	1 (25.0%)
Respiration Failure,n (%)			
No	0 (0.0%)	1 (50.0%)	1 (25.0%)
Yes	2 (100.0%)	1 (50.0%)	3 (75.0%)
Circulation Failure, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

[1]Chi-Square p-value;

	Center Order 36		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	2 (50.0%)	1 (25.0%)	3 (37.5%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	2 (50.0%)	2 (25.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (50.0%)	1 (25.0%)	3 (37.5%)

Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Urinary tract infection,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Circulation Failure, n (%)			

No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

[1]Chi-Square p-value;

	Center Order 37		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	2 (50.0%)	1 (25.0%)	3 (37.5%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	1 (25.0%)	1 (12.5%)
5	1 (25.0%)	1 (25.0%)	2 (25.0%)
6	1 (25.0%)	1 (25.0%)	2 (25.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (75.0%)	0 (0.0%)	3 (37.5%)
Yes	1 (25.0%)	4 (100.0%)	5 (62.5%)
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	1 (25.0%)	1 (12.5%)
Insulin Use in Hospital Stay,n (%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%)
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%)
Craniectomy,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Respiration Failure,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%)
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

[1]Chi-Square p-value;

	Center Order 38		
	Group		
	Methylprednisolone (N=12)	Placebo (N=12)	Total (N=24)
modified Rankin Scale score at 90 days,n (%)			
0	1 (8.3%)	1 (8.3%)	2 (8.3%)
1	1 (8.3%)	3 (25.0%)	4 (16.7%)
2	2 (16.7%)	1 (8.3%)	3 (12.5%)
3	3 (25.0%)	3 (25.0%)	6 (25.0%)
4	2 (16.7%)	2 (16.7%)	4 (16.7%)
5	1 (8.3%)	0 (0.0%)	1 (4.2%)
6	2 (16.7%)	2 (16.7%)	4 (16.7%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	10 (83.3%)	11 (91.7%)	21 (87.5%)
Yes	2 (16.7%)	1 (8.3%)	3 (12.5%)

Missing	0	0	0
Pneumonia,n (%)			
No	8 (66.7%)	5 (41.7%)	13 (54.2%)
Yes	4 (33.3%)	7 (58.3%)	11 (45.8%)
Urinary tract infection,n (%)			
No	12 (100.0%)	10 (83.3%)	22 (91.7%)
Yes	0 (0.0%)	2 (16.7%)	2 (8.3%)
Other Infection,n (%)			
No	12 (100.0%)	11 (91.7%)	23 (95.8%)
Yes	0 (0.0%)	1 (8.3%)	1 (4.2%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	9 (75.0%)	12 (100.0%)	21 (87.5%)
Pseudoaneurysm	1 (8.3%)	0 (0.0%)	1 (4.2%)
Puncture site hematoma	2 (16.7%)	0 (0.0%)	2 (8.3%)
Insulin Use in Hospital Stay,n (%)			
No	10 (83.3%)	11 (91.7%)	21 (87.5%)
Yes	2 (16.7%)	1 (8.3%)	3 (12.5%)
Craniectomy,n (%)			
No	11 (91.7%)	12 (100.0%)	23 (95.8%)
Yes	1 (8.3%)	0 (0.0%)	1 (4.2%)
Respiration Failure,n (%)			
No	9 (75.0%)	10 (83.3%)	19 (79.2%)
Yes	3 (25.0%)	2 (16.7%)	5 (20.8%)
Circulation Failure, n (%)			
No	10 (83.3%)	11 (91.7%)	21 (87.5%)
Yes	2 (16.7%)	1 (8.3%)	3 (12.5%)

[1]Chi-Square p-value;

	Center Order 39		
	Group		
	Methylprednisolone (N=18)	Placebo (N=18)	Total (N=36)
modified Rankin Scale score at 90 days,n (%)			
0	1 (5.6%)	2 (11.1%)	3 (8.3%)
1	4 (22.2%)	3 (16.7%)	7 (19.4%)
2	1 (5.6%)	3 (16.7%)	4 (11.1%)
3	4 (22.2%)	1 (5.6%)	5 (13.9%)
4	2 (11.1%)	3 (16.7%)	5 (13.9%)
5	1 (5.6%)	1 (5.6%)	2 (5.6%)
6	5 (27.8%)	5 (27.8%)	10 (27.8%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	17 (94.4%)	15 (83.3%)	32 (88.9%)
Yes	1 (5.6%)	3 (16.7%)	4 (11.1%)
Missing	0	0	0
Pneumonia,n (%)			
No	12 (66.7%)	10 (55.6%)	22 (61.1%)
Yes	6 (33.3%)	8 (44.4%)	14 (38.9%)
Urinary tract infection,n (%)			
No	18 (100.0%)	17 (94.4%)	35 (97.2%)
Yes	0 (0.0%)	1 (5.6%)	1 (2.8%)
Other Infection,n (%)			
No	18 (100.0%)	18 (100.0%)	36 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	18 (100.0%)	16 (88.9%)	34 (94.4%)
Yes	0 (0.0%)	2 (11.1%)	2 (5.6%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	18 (100.0%)	18 (100.0%)	36 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)

Insulin Use in Hospital Stay,n (%)			
No	14 (77.8%)	17 (94.4%)	31 (86.1%)
Yes	4 (22.2%)	1 (5.6%)	5 (13.9%)
Craniectomy,n (%)			
No	18 (100.0%)	18 (100.0%)	36 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	15 (83.3%)	11 (61.1%)	26 (72.2%)
Yes	3 (16.7%)	7 (38.9%)	10 (27.8%)
Circulation Failure, n (%)			
No	17 (94.4%)	14 (77.8%)	31 (86.1%)
Yes	1 (5.6%)	4 (22.2%)	5 (13.9%)

[1]Chi-Square p-value;

	Center Order 40		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (25.0%)	1 (12.5%)
1	0 (0.0%)	1 (25.0%)	1 (12.5%)
2	0 (0.0%)	1 (25.0%)	1 (12.5%)
3	0 (0.0%)	1 (25.0%)	1 (12.5%)
4	1 (25.0%)	0 (0.0%)	1 (12.5%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (75.0%)	0 (0.0%)	3 (37.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	2 (50.0%)	2 (50.0%)	4 (50.0%)
Yes	2 (50.0%)	2 (50.0%)	4 (50.0%)

Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Pseudoaneurysm	0 (0.0%)	1 (25.0%)	1 (12.5%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%)
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

[1]Chi-Square p-value;

	Center Order 41		
	Group		
	Methylprednisolone (N=20)	Placebo (N=20)	Total (N=40)

modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (5.0%)	1 (2.6%)
1	2 (10.5%)	1 (5.0%)	3 (7.7%)
2	2 (10.5%)	2 (10.0%)	4 (10.3%)
3	6 (31.6%)	4 (20.0%)	10 (25.6%)
4	4 (21.1%)	4 (20.0%)	8 (20.5%)	
5	0 (0.0%)	1 (5.0%)	1 (2.6%)
6	5 (26.3%)	7 (35.0%)	12 (30.8%)
Missing	1	0	1
Symptomatic intracranial hemorrhage, n (%)			
No	18 (90.0%)	17 (85.0%)	35 (87.5%)
Yes	2 (10.0%)	3 (15.0%)	5 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	6 (30.0%)	7 (35.0%)	13 (32.5%)
Yes	14 (70.0%)	13 (65.0%)	27 (67.5%)
Urinary tract infection,n (%)			
No	15 (75.0%)	15 (75.0%)	30 (75.0%)
Yes	5 (25.0%)	5 (25.0%)	10 (25.0%)
Other Infection,n (%)			
No	20 (100.0%)	20 (100.0%)	40 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	20 (100.0%)	20 (100.0%)	40 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	18 (90.0%)	20 (100.0%)	38 (95.0%)
Pseudoaneurysm	2 (10.0%)	0 (0.0%)	2 (5.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	18 (90.0%)	20 (100.0%)	38 (95.0%)
Yes	2 (10.0%)	0 (0.0%)	2 (5.0%)

Craniectomy,n (%)			
No	19 (95.0%)	19 (95.0%)	38 (95.0%)
Yes	1 (5.0%)	1 (5.0%)	2 (5.0%)
Respiration Failure,n (%)			
No	18 (90.0%)	15 (75.0%)	33 (82.5%)
Yes	2 (10.0%)	5 (25.0%)	7 (17.5%)
Circulation Failure, n (%)			
No	20 (100.0%)	18 (90.0%)	38 (95.0%)
Yes	0 (0.0%)	2 (10.0%)	2 (5.0%)

[1]Chi-Square p-value;

	Center Order 42		
	Group		
	Methylprednisolone (N=66)	Placebo (N=67)	Total (N=133)
modified Rankin Scale score at 90 days,n (%)			
0	4 (6.1%)	7 (10.4%)	11 (8.3%)
1	12 (18.2%)	11 (16.4%)	23 (17.3%)
2	7 (10.6%)	9 (13.4%)	16 (12.0%)
3	9 (13.6%)	8 (11.9%)	17 (12.8%)
4	8 (12.1%)	12 (17.9%)	20 (15.0%)
5	9 (13.6%)	6 (9.0%)	15 (11.3%)
6	17 (25.8%)	14 (20.9%)	31 (23.3%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	58 (89.2%)	59 (90.8%)	117 (90.0%)
Yes	7 (10.8%)	6 (9.2%)	13 (10.0%)
Missing	1	2	3
Pneumonia,n (%)			
No	36 (54.5%)	47 (70.1%)	83 (62.4%)
Yes	30 (45.5%)	20 (29.9%)	50 (37.6%)
Urinary tract infection,n (%)			
No	65 (98.5%)	65 (97.0%)	130 (97.7%)
Yes	1 (1.5%)	2 (3.0%)	3 (2.3%)
Other Infection,n (%)			

No	66 (100.0%)	67 (100.0%)	133 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	64 (97.0%)	66 (98.5%)	130 (97.7%)
Yes	2 (3.0%)	1 (1.5%)	3 (2.3%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	65 (98.5%)	66 (98.5%)	131 (98.5%)
Pseudoaneurysm	1 (1.5%)	1 (1.5%)	2 (1.5%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	60 (90.9%)	62 (92.5%)	122 (91.7%)
Yes	6 (9.1%)	5 (7.5%)	11 (8.3%)
Craniectomy,n (%)			
No	62 (93.9%)	64 (95.5%)	126 (94.7%)
Yes	4 (6.1%)	3 (4.5%)	7 (5.3%)
Respiration Failure,n (%)			
No	50 (75.8%)	53 (79.1%)	103 (77.4%)
Yes	16 (24.2%)	14 (20.9%)	30 (22.6%)
Circulation Failure, n (%)			
No	55 (83.3%)	62 (92.5%)	117 (88.0%)
Yes	11 (16.7%)	5 (7.5%)	16 (12.0%)

[1]Chi-Square p-value;

	Center Order 43		
	Group		
	Methylprednisolone (N=10)	Placebo (N=9)	Total (N=19)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (10.0%)	2 (22.2%)	3 (15.8%)
2	3 (30.0%)	1 (11.1%)	4 (21.1%)

3	4 (40.0%)	3 (33.3%)	7 (36.8%)
4	0 (0.0%)	1 (11.1%)	1 (5.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (20.0%)	2 (22.2%)	4 (21.1%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	10 (100.0%)	8 (88.9%)	18 (94.7%)
Yes	0 (0.0%)	1 (11.1%)	1 (5.3%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (40.0%)	3 (33.3%)	7 (36.8%)
Yes	6 (60.0%)	6 (66.7%)	12 (63.2%)
Urinary tract infection,n (%)			
No	10 (100.0%)	9 (100.0%)	19 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	10 (100.0%)	9 (100.0%)	19 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	10 (100.0%)	8 (88.9%)	18 (94.7%)
Yes	0 (0.0%)	1 (11.1%)	1 (5.3%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	10 (100.0%)	9 (100.0%)	19 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	9 (90.0%)	7 (77.8%)	16 (84.2%)
Yes	1 (10.0%)	2 (22.2%)	3 (15.8%)
Craniectomy,n (%)			
No	10 (100.0%)	9 (100.0%)	19 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			

No	9 (90.0%)	8 (88.9%)	17 (89.5%)
Yes	1 (10.0%)	1 (11.1%)	2 (10.5%)
Circulation Failure, n (%)			
No	10 (100.0%)	7 (77.8%)	17 (89.5%)
Yes	0 (0.0%)	2 (22.2%)	2 (10.5%)

[1]Chi-Square p-value;

	Center Order 44		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (25.0%)	1 (12.5%)
1	1 (25.0%)	0 (0.0%)	1 (12.5%)
2	1 (25.0%)	0 (0.0%)	1 (12.5%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (50.0%)	3 (75.0%)	5 (62.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	2 (100.0%)	6 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	2	2
Pneumonia,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			

No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%)
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

[1]Chi-Square p-value;

	Center Order 45		
	Group		
	Methylprednisolone (N=9)	Placebo (N=10)	Total (N=19)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (22.2%)	2 (11.8%)
1	2 (25.0%)	2 (22.2%)	4 (23.5%)
2	2 (25.0%)	1 (11.1%)	3 (17.6%)
3	0 (0.0%)	1 (11.1%)	1 (5.9%)
4	2 (25.0%)	0 (0.0%)	2 (11.8%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (25.0%)	3 (33.3%)	5 (29.4%)
Missing	1	1	2

Symptomatic intracranial hemorrhage, n (%)			
No	9 (100.0%)	10 (100.0%)	19 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	5 (55.6%)	8 (80.0%)	13 (68.4%)
Yes	4 (44.4%)	2 (20.0%)	6 (31.6%)
Urinary tract infection,n (%)			
No	6 (66.7%)	8 (80.0%)	14 (73.7%)
Yes	3 (33.3%)	2 (20.0%)	5 (26.3%)
Other Infection,n (%)			
No	8 (88.9%)	9 (90.0%)	17 (89.5%)
Yes	1 (11.1%)	1 (10.0%)	2 (10.5%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	9 (100.0%)	9 (90.0%)	18 (94.7%)
Yes	0 (0.0%)	1 (10.0%)	1 (5.3%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	9 (100.0%)	10 (100.0%)	19 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	8 (88.9%)	7 (70.0%)	15 (78.9%)
Yes	1 (11.1%)	3 (30.0%)	4 (21.1%)
Craniectomy,n (%)			
No	8 (88.9%)	10 (100.0%)	18 (94.7%)
Yes	1 (11.1%)	0 (0.0%)	1 (5.3%)
Respiration Failure,n (%)			
No	8 (88.9%)	8 (80.0%)	16 (84.2%)
Yes	1 (11.1%)	2 (20.0%)	3 (15.8%)
Circulation Failure, n (%)			
No	6 (66.7%)	8 (80.0%)	14 (73.7%)
Yes	3 (33.3%)	2 (20.0%)	5 (26.3%)

[1]Chi-Square p-value;

	Center Order 46		
	Group		
	Methylprednisolone (N=8)	Placebo (N=8)	Total (N=16)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (12.5%)	1 (6.3%)
1	1 (12.5%)	1 (12.5%)	2 (12.5%)
2	4 (50.0%)	2 (25.0%)	6 (37.5%)
3	0 (0.0%)	1 (12.5%)	1 (6.3%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (37.5%)	3 (37.5%)	6 (37.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (50.0%)	4 (50.0%)	8 (50.0%)
Yes	4 (50.0%)	4 (50.0%)	8 (50.0%)
Urinary tract infection,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Other Infection,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)

No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	6 (75.0%)	7 (87.5%)	13 (81.3%)
Yes	2 (25.0%)	1 (12.5%)	3 (18.8%)
Craniectomy,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Respiration Failure,n (%)			
No	6 (75.0%)	6 (75.0%)	12 (75.0%)
Yes	2 (25.0%)	2 (25.0%)	4 (25.0%)
Circulation Failure, n (%)			
No	6 (75.0%)	5 (62.5%)	11 (68.8%)
Yes	2 (25.0%)	3 (37.5%)	5 (31.3%)

[1]Chi-Square p-value;

	Center Order		
	48		
	Group		
	Methylprednisolone	Placebo	Total
	(N=12)	(N=12)	(N=24)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (8.3%)	1 (4.2%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	5 (41.7%)	3 (25.0%)	8 (33.3%)
4	2 (16.7%)	0 (0.0%)	2 (8.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	5 (41.7%)	8 (66.7%)	13 (54.2%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	8 (80.0%)	11 (91.7%)	19 (86.4%)
Yes	2 (20.0%)	1 (8.3%)	3 (13.6%)
Missing	2	0	2
Pneumonia,n (%)			

No	3 (25.0%)	4 (33.3%)	7 (29.2%)
Yes	9 (75.0%)	8 (66.7%)	17 (70.8%)
Urinary tract infection,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	12 (100.0%)	11 (91.7%)	23 (95.8%)
Yes	0 (0.0%)	1 (8.3%)	1 (4.2%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	11 (91.7%)	11 (91.7%)	22 (91.7%)
Yes	1 (8.3%)	1 (8.3%)	2 (8.3%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	7 (58.3%)	10 (83.3%)	17 (70.8%)
Yes	5 (41.7%)	2 (16.7%)	7 (29.2%)
Craniectomy,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	6 (50.0%)	7 (58.3%)	13 (54.2%)
Yes	6 (50.0%)	5 (41.7%)	11 (45.8%)
Circulation Failure, n (%)			
No	8 (66.7%)	9 (75.0%)	17 (70.8%)
Yes	4 (33.3%)	3 (25.0%)	7 (29.2%)

[1]Chi-Square p-value;

	Center Order
	49
	Group

	Methylprednisolone (N=6)	Placebo (N=7)	Total (N=13)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (14.3%)	1 (7.7%)
1	2 (33.3%)	1 (14.3%)	3 (23.1%)
2	2 (33.3%)	1 (14.3%)	3 (23.1%)
3	0 (0.0%)	1 (14.3%)	1 (7.7%)
4	0 (0.0%)	1 (14.3%)	1 (7.7%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (33.3%)	2 (28.6%)	4 (30.8%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	5 (100.0%)	5 (71.4%)	10 (83.3%)
Yes	0 (0.0%)	2 (28.6%)	2 (16.7%)
Missing	1	0	1
Pneumonia,n (%)			
No	6 (100.0%)	2 (28.6%)	8 (61.5%)
Yes	0 (0.0%)	5 (71.4%)	5 (38.5%)
Urinary tract infection,n (%)			
No	5 (83.3%)	7 (100.0%)	12 (92.3%)
Yes	1 (16.7%)	0 (0.0%)	1 (7.7%)
Other Infection,n (%)			
No	5 (83.3%)	7 (100.0%)	12 (92.3%)
Yes	1 (16.7%)	0 (0.0%)	1 (7.7%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	6 (100.0%)	7 (100.0%)	13 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	6 (100.0%)	7 (100.0%)	13 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	6 (100.0%)	5 (71.4%)	11 (84.6%)

Yes	0 (0.0%)	2 (28.6%)	2 (15.4%)
Craniectomy,n (%)			
No	5 (83.3%)	6 (85.7%)	11 (84.6%)
Yes	1 (16.7%)	1 (14.3%)	2 (15.4%)
Respiration Failure,n (%)			
No	5 (83.3%)	5 (71.4%)	10 (76.9%)
Yes	1 (16.7%)	2 (28.6%)	3 (23.1%)
Circulation Failure, n (%)			
No	5 (83.3%)	6 (85.7%)	11 (84.6%)
Yes	1 (16.7%)	1 (14.3%)	2 (15.4%)

[1]Chi-Square p-value;

	Center Order 51		
	Group		
	Methylprednisolone (N=8)	Placebo (N=8)	Total (N=16)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (12.5%)	0 (0.0%)	1 (6.3%)
2	4 (50.0%)	0 (0.0%)	4 (25.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	1 (12.5%)	1 (6.3%)
5	2 (25.0%)	1 (12.5%)	3 (18.8%)
6	1 (12.5%)	6 (75.0%)	7 (43.8%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	6 (75.0%)	7 (87.5%)	13 (81.3%)
Yes	2 (25.0%)	1 (12.5%)	3 (18.8%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (37.5%)	2 (25.0%)	5 (31.3%)
Yes	5 (62.5%)	6 (75.0%)	11 (68.8%)
Urinary tract infection,n (%)			
No	7 (87.5%)	6 (75.0%)	13 (81.3%)
Yes	1 (12.5%)	2 (25.0%)	3 (18.8%)

Other Infection,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	7 (87.5%)	5 (62.5%)	12 (75.0%)
Yes	1 (12.5%)	3 (37.5%)	4 (25.0%)
Craniectomy,n (%)			
No	6 (75.0%)	7 (87.5%)	13 (81.3%)
Yes	2 (25.0%)	1 (12.5%)	3 (18.8%)
Respiration Failure,n (%)			
No	5 (62.5%)	4 (50.0%)	9 (56.3%)
Yes	3 (37.5%)	4 (50.0%)	7 (43.8%)
Circulation Failure, n (%)			
No	5 (62.5%)	6 (75.0%)	11 (68.8%)
Yes	3 (37.5%)	2 (25.0%)	5 (31.3%)

[1]Chi-Square p-value;

	Center Order 52		
	Group		
	Methylprednisolone (N=10)	Placebo (N=10)	Total (N=20)
modified Rankin Scale score at 90 days,n (%)			
0	1 (10.0%)	1 (10.0%)	2 (10.0%)
1	6 (60.0%)	2 (20.0%)	8 (40.0%)

2	1 (10.0%)	0 (0.0%)	1 (5.0%)
3	1 (10.0%)	3 (30.0%)	4 (20.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	1 (10.0%)	1 (5.0%)
6	1 (10.0%)	3 (30.0%)	4 (20.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	10 (100.0%)	8 (88.9%)	18 (94.7%)
Yes	0 (0.0%)	1 (11.1%)	1 (5.3%)
Missing	0	1	1
Pneumonia,n (%)			
No	8 (80.0%)	5 (50.0%)	13 (65.0%)
Yes	2 (20.0%)	5 (50.0%)	7 (35.0%)
Urinary tract infection,n (%)			
No	9 (90.0%)	7 (70.0%)	16 (80.0%)
Yes	1 (10.0%)	3 (30.0%)	4 (20.0%)
Other Infection,n (%)			
No	9 (90.0%)	10 (100.0%)	19 (95.0%)
Yes	1 (10.0%)	0 (0.0%)	1 (5.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	10 (100.0%)	9 (90.0%)	19 (95.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	1 (10.0%)	1 (5.0%)
Insulin Use in Hospital Stay,n (%)			
No	9 (90.0%)	6 (60.0%)	15 (75.0%)
Yes	1 (10.0%)	4 (40.0%)	5 (25.0%)
Craniectomy,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Respiration Failure,n (%)			
No	10 (100.0%)	8 (80.0%)	18 (90.0%)
Yes	0 (0.0%)	2 (20.0%)	2 (10.0%)
Circulation Failure, n (%)			
No	10 (100.0%)	9 (90.0%)	19 (95.0%)
Yes	0 (0.0%)	1 (10.0%)	1 (5.0%)

[1]Chi-Square p-value;

	Center Order 53		
	Group		
	Methylprednisolone (N=24)	Placebo (N=24)	Total (N=48)
modified Rankin Scale score at 90 days,n (%)			
0	1 (4.2%)	1 (4.2%)	2 (4.2%)
1	5 (20.8%)	1 (4.2%)	6 (12.5%)
2	4 (16.7%)	4 (16.7%)	8 (16.7%)
3	6 (25.0%)	3 (12.5%)	9 (18.8%)
4	2 (8.3%)	6 (25.0%)	8 (16.7%)
5	0 (0.0%)	2 (8.3%)	2 (4.2%)
6	6 (25.0%)	7 (29.2%)	13 (27.1%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	18 (78.3%)	20 (83.3%)	38 (80.9%)
Yes	5 (21.7%)	4 (16.7%)	9 (19.1%)
Missing	1	0	1
Pneumonia,n (%)			
No	7 (29.2%)	6 (25.0%)	13 (27.1%)
Yes	17 (70.8%)	18 (75.0%)	35 (72.9%)
Urinary tract infection,n (%)			
No	20 (83.3%)	22 (91.7%)	42 (87.5%)
Yes	4 (16.7%)	2 (8.3%)	6 (12.5%)
Other Infection,n (%)			
No	21 (87.5%)	22 (91.7%)	43 (89.6%)
Yes	3 (12.5%)	2 (8.3%)	5 (10.4%)

Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	20 (83.3%)	20 (83.3%)	40 (83.3%)
Yes	4 (16.7%)	4 (16.7%)	8 (16.7%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	24 (100.0%)	24 (100.0%)	48 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	18 (75.0%)	19 (79.2%)	37 (77.1%)
Yes	6 (25.0%)	5 (20.8%)	11 (22.9%)
Craniectomy,n (%)			
No	23 (95.8%)	22 (91.7%)	45 (93.8%)
Yes	1 (4.2%)	2 (8.3%)	3 (6.3%)
Respiration Failure,n (%)			
No	17 (70.8%)	16 (66.7%)	33 (68.8%)
Yes	7 (29.2%)	8 (33.3%)	15 (31.3%)
Circulation Failure, n (%)			
No	22 (91.7%)	20 (83.3%)	42 (87.5%)
Yes	2 (8.3%)	4 (16.7%)	6 (12.5%)

[1]Chi-Square p-value;

	Center Order 55		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	1 (25.0%)	1 (25.0%)	2 (25.0%)
1	1 (25.0%)	0 (0.0%)	1 (12.5%)
2	1 (25.0%)	0 (0.0%)	1 (12.5%)
3	0 (0.0%)	1 (25.0%)	1 (12.5%)
4	1 (25.0%)	1 (25.0%)	2 (25.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	0 (0.0%)	1 (25.0%)	1 (12.5%)

Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (100.0%)	2 (50.0%)	6 (75.0%)
Yes	0 (0.0%)	2 (50.0%)	2 (25.0%)
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	3 (75.0%)	2 (50.0%)	5 (62.5%)
Yes	1 (25.0%)	2 (50.0%)	3 (37.5%)
Craniectomy,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%)
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)
Respiration Failure,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%)
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)
Circulation Failure, n (%)			

No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)

[1]Chi-Square p-value;

	Center Order 56		
	Group		
	Methylprednisolone (N=10)	Placebo (N=10)	Total (N=20)
modified Rankin Scale score at 90 days,n (%)			
0	2 (20.0%)	0 (0.0%)	2 (10.0%)
1	4 (40.0%)	2 (20.0%)	6 (30.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	3 (30.0%)	3 (15.0%)
4	1 (10.0%)	2 (20.0%)	3 (15.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (30.0%)	3 (30.0%)	6 (30.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	8 (88.9%)	9 (90.0%)	17 (89.5%)
Yes	1 (11.1%)	1 (10.0%)	2 (10.5%)
Missing	1	0	1
Pneumonia,n (%)			
No	6 (60.0%)	4 (40.0%)	10 (50.0%)
Yes	4 (40.0%)	6 (60.0%)	10 (50.0%)
Urinary tract infection,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	10 (100.0%)	9 (90.0%)	19 (95.0%)
Yes	0 (0.0%)	1 (10.0%)	1 (5.0%)

Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	8 (80.0%)	8 (80.0%)	16 (80.0%)
Yes	2 (20.0%)	2 (20.0%)	4 (20.0%)
Craniectomy,n (%)			
No	9 (90.0%)	9 (90.0%)	18 (90.0%)
Yes	1 (10.0%)	1 (10.0%)	2 (10.0%)
Respiration Failure,n (%)			
No	7 (70.0%)	6 (60.0%)	13 (65.0%)
Yes	3 (30.0%)	4 (40.0%)	7 (35.0%)
Circulation Failure, n (%)			
No	7 (70.0%)	4 (40.0%)	11 (55.0%)
Yes	3 (30.0%)	6 (60.0%)	9 (45.0%)

[1]Chi-Square p-value;

	Center Order 58		
	Group		
	Methylprednisolone (N=17)	Placebo (N=18)	Total (N=35)
modified Rankin Scale score at 90 days,n (%)			
0	1 (5.9%)	0 (0.0%)	1 (2.9%)
1	2 (11.8%)	3 (16.7%)	5 (14.3%)
2	2 (11.8%)	0 (0.0%)	2 (5.7%)
3	6 (35.3%)	2 (11.1%)	8 (22.9%)
4	2 (11.8%)	1 (5.6%)	3 (8.6%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	4 (23.5%)	12 (66.7%)	16 (45.7%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	15 (93.8%)	15 (83.3%)	30 (88.2%)
Yes	1 (6.3%)	3 (16.7%)	4 (11.8%)

Missing	1	0	1
Pneumonia,n (%)			
No	8 (47.1%)	4 (22.2%)	12 (34.3%)
Yes	9 (52.9%)	14 (77.8%)	23 (65.7%)
Urinary tract infection,n (%)			
No	13 (76.5%)	18 (100.0%)	31 (88.6%)
Yes	4 (23.5%)	0 (0.0%)	4 (11.4%)
Other Infection,n (%)			
No	16 (94.1%)	17 (94.4%)	33 (94.3%)
Yes	1 (5.9%)	1 (5.6%)	2 (5.7%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	16 (94.1%)	17 (94.4%)	33 (94.3%)
Yes	1 (5.9%)	1 (5.6%)	2 (5.7%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	17 (100.0%)	18 (100.0%)	35 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	12 (70.6%)	16 (88.9%)	28 (80.0%)
Yes	5 (29.4%)	2 (11.1%)	7 (20.0%)
Craniectomy,n (%)			
No	16 (94.1%)	16 (88.9%)	32 (91.4%)
Yes	1 (5.9%)	2 (11.1%)	3 (8.6%)
Respiration Failure,n (%)			
No	13 (76.5%)	8 (44.4%)	21 (60.0%)
Yes	4 (23.5%)	10 (55.6%)	14 (40.0%)
Circulation Failure, n (%)			
No	13 (76.5%)	9 (50.0%)	22 (62.9%)
Yes	4 (23.5%)	9 (50.0%)	13 (37.1%)

[1]Chi-Square p-value;

	Center Order 59		
	Group		
	Methylprednisolone (N=2)	Placebo (N=2)	Total (N=4)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	2 (100.0%)	0 (0.0%)	2 (50.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	1 (50.0%)	1 (25.0%)
6	0 (0.0%)	1 (50.0%)	1 (25.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	0 (0.0%)	0 (0.0%)	0 (0.0%)
Yes	2 (100.0%)	2 (100.0%)	4 (100.0%)
Urinary tract infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)

Insulin Use in Hospital Stay,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Respiration Failure,n (%)			
No	2 (100.0%)	0 (0.0%)	2 (50.0%)
Yes	0 (0.0%)	2 (100.0%)	2 (50.0%)
Circulation Failure, n (%)			
No	2 (100.0%)	0 (0.0%)	2 (50.0%)
Yes	0 (0.0%)	2 (100.0%)	2 (50.0%)

[1]Chi-Square p-value;

	Center Order		
	60		
	Group		
	Methylprednisolone (N=12)	Placebo (N=12)	Total (N=24)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	3 (25.0%)	4 (33.3%)	7 (29.2%)
2	4 (33.3%)	0 (0.0%)	4 (16.7%)
3	1 (8.3%)	3 (25.0%)	4 (16.7%)
4	2 (16.7%)	3 (25.0%)	5 (20.8%)
5	0 (0.0%)	1 (8.3%)	1 (4.2%)
6	2 (16.7%)	1 (8.3%)	3 (12.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	11 (100.0%)	12 (100.0%)	23 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	1	0	1
Pneumonia,n (%)			
No	4 (33.3%)	5 (41.7%)	9 (37.5%)
Yes	8 (66.7%)	7 (58.3%)	15 (62.5%)

Urinary tract infection,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	11 (91.7%)	12 (100.0%)	23 (95.8%)
Yes	1 (8.3%)	0 (0.0%)	1 (4.2%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	12 (100.0%)	12 (100.0%)	24 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	10 (83.3%)	11 (91.7%)	21 (87.5%)
Yes	2 (16.7%)	1 (8.3%)	3 (12.5%)
Craniectomy,n (%)			
No	12 (100.0%)	11 (91.7%)	23 (95.8%)
Yes	0 (0.0%)	1 (8.3%)	1 (4.2%)
Respiration Failure,n (%)			
No	10 (83.3%)	9 (75.0%)	19 (79.2%)
Yes	2 (16.7%)	3 (25.0%)	5 (20.8%)
Circulation Failure, n (%)			
No	11 (91.7%)	12 (100.0%)	23 (95.8%)
Yes	1 (8.3%)	0 (0.0%)	1 (4.2%)

[1]Chi-Square p-value;

	Center Order 61		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)

modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (25.0%)	1 (12.5%)
2	2 (50.0%)	0 (0.0%)	2 (25.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	1 (25.0%)	1 (25.0%)	2 (25.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (25.0%)	2 (50.0%)	3 (37.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	1	0	1
Pneumonia,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%)
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%)
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

Craniectomy,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Respiration Failure,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%)
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)
Circulation Failure, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)

[1]Chi-Square p-value;

	Center Order		
	62		
	Group		
	Methylprednisolone	Placebo	Total
	(N=2)	(N=2)	(N=4)
modified Rankin Scale score at 90 days,n (%)			
0	1 (50.0%)	0 (0.0%)	1 (25.0%)
1	0 (0.0%)	1 (50.0%)	1 (25.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (50.0%)	1 (50.0%)	2 (50.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	1 (50.0%)	1 (50.0%)	2 (50.0%)
Yes	1 (50.0%)	1 (50.0%)	2 (50.0%)
Urinary tract infection,n (%)			
No	1 (50.0%)	2 (100.0%)	3 (75.0%)
Yes	1 (50.0%)	0 (0.0%)	1 (25.0%)
Other Infection,n (%)			

No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	1 (50.0%)	1 (50.0%)	2 (50.0%)
Yes	1 (50.0%)	1 (50.0%)	2 (50.0%)
Respiration Failure,n (%)			
No	1 (50.0%)	1 (50.0%)	2 (50.0%)
Yes	1 (50.0%)	1 (50.0%)	2 (50.0%)
Circulation Failure, n (%)			
No	1 (50.0%)	0 (0.0%)	1 (25.0%)
Yes	1 (50.0%)	2 (100.0%)	3 (75.0%)

[1]Chi-Square p-value;

	Center Order 64		
	Group		
	Methylprednisolone (N=6)	Placebo (N=6)	Total (N=12)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (16.7%)	0 (0.0%)	1 (8.3%)
2	0 (0.0%)	1 (16.7%)	1 (8.3%)
3	1 (16.7%)	0 (0.0%)	1 (8.3%)

4	2 (33.3%)	2 (33.3%)	4 (33.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (33.3%)	3 (50.0%)	5 (41.7%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	5 (100.0%)	5 (83.3%)	10 (90.9%)
Yes	0 (0.0%)	1 (16.7%)	1 (9.1%)
Missing	1	0	1
Pneumonia,n (%)			
No	2 (33.3%)	2 (33.3%)	4 (33.3%)
Yes	4 (66.7%)	4 (66.7%)	8 (66.7%)
Urinary tract infection,n (%)			
No	5 (83.3%)	5 (83.3%)	10 (83.3%)
Yes	1 (16.7%)	1 (16.7%)	2 (16.7%)
Other Infection,n (%)			
No	6 (100.0%)	6 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	6 (100.0%)	6 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	6 (100.0%)	6 (100.0%)	12 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	5 (83.3%)	3 (50.0%)	8 (66.7%)
Yes	1 (16.7%)	3 (50.0%)	4 (33.3%)
Craniectomy,n (%)			
No	6 (100.0%)	6 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (66.7%)	2 (33.3%)	6 (50.0%)

Yes	2 (33.3%)	4 (66.7%)	6 (50.0%)
Circulation Failure, n (%)			
No	5 (83.3%)	2 (33.3%)	7 (58.3%)
Yes	1 (16.7%)	4 (66.7%)	5 (41.7%)

[1]Chi-Square p-value;

	Center Order 65		
	Group		
	Methylprednisolone (N=3)	Placebo (N=4)	Total (N=7)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (25.0%)	1 (14.3%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	1 (25.0%)	1 (14.3%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	1 (33.3%)	0 (0.0%)	1 (14.3%)
6	2 (66.7%)	2 (50.0%)	4 (57.1%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	1 (33.3%)	3 (75.0%)	4 (57.1%)
Yes	2 (66.7%)	1 (25.0%)	3 (42.9%)
Urinary tract infection,n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.0%)

Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	3 (100.0%)	4 (100.0%)	7 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	1 (33.3%)	4 (100.0%)	5 (71.4%)
Yes	2 (66.7%)	0 (0.0%)	2 (28.6%)
Craniectomy,n (%)			
No	2 (66.7%)	4 (100.0%)	6 (85.7%)
Yes	1 (33.3%)	0 (0.0%)	1 (14.3%)
Respiration Failure,n (%)			
No	1 (33.3%)	3 (75.0%)	4 (57.1%)
Yes	2 (66.7%)	1 (25.0%)	3 (42.9%)
Circulation Failure, n (%)			
No	1 (33.3%)	3 (75.0%)	4 (57.1%)
Yes	2 (66.7%)	1 (25.0%)	3 (42.9%)

[1]Chi-Square p-value;

	Center Order 67		
	Group		
	Methylprednisolone (N=5)	Placebo (N=4)	Total (N=9)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (25.0%)	1 (12.5%)
2	0 (0.0%)	1 (25.0%)	1 (12.5%)
3	1 (25.0%)	1 (25.0%)	2 (25.0%)
4	0 (0.0%)	1 (25.0%)	1 (12.5%)
5	2 (50.0%)	0 (0.0%)	2 (25.0%)
6	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	1	0	1
Symptomatic intracranial hemorrhage, n (%)			

No	5 (100.0%)	4 (100.0%)	9 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (60.0%)	4 (100.0%)	7 (77.8%)
Yes	2 (40.0%)	0 (0.0%)	2 (22.2%)
Urinary tract infection,n (%)			
No	5 (100.0%)	4 (100.0%)	9 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (80.0%)	4 (100.0%)	8 (88.9%)
Yes	1 (20.0%)	0 (0.0%)	1 (11.1%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	5 (100.0%)	4 (100.0%)	9 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	5 (100.0%)	4 (100.0%)	9 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (80.0%)	4 (100.0%)	8 (88.9%)
Yes	1 (20.0%)	0 (0.0%)	1 (11.1%)
Craniectomy,n (%)			
No	5 (100.0%)	4 (100.0%)	9 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	3 (60.0%)	2 (50.0%)	5 (55.6%)
Yes	2 (40.0%)	2 (50.0%)	4 (44.4%)
Circulation Failure, n (%)			
No	4 (80.0%)	4 (100.0%)	8 (88.9%)
Yes	1 (20.0%)	0 (0.0%)	1 (11.1%)

[1]Chi-Square p-value;

	Center Order 68		
	Group		
	Methylprednisolone (N=15)	Placebo (N=16)	Total (N=31)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (12.5%)	2 (6.5%)
1	6 (40.0%)	1 (6.3%)	7 (22.6%)
2	2 (13.3%)	3 (18.8%)	5 (16.1%)
3	1 (6.7%)	1 (6.3%)	2 (6.5%)
4	2 (13.3%)	2 (12.5%)	4 (12.9%)
5	1 (6.7%)	2 (12.5%)	3 (9.7%)
6	3 (20.0%)	5 (31.3%)	8 (25.8%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	15 (100.0%)	12 (75.0%)	27 (87.1%)
Yes	0 (0.0%)	4 (25.0%)	4 (12.9%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (26.7%)	1 (6.3%)	5 (16.1%)
Yes	11 (73.3%)	15 (93.8%)	26 (83.9%)
Urinary tract infection,n (%)			
No	12 (80.0%)	16 (100.0%)	28 (90.3%)
Yes	3 (20.0%)	0 (0.0%)	3 (9.7%)
Other Infection,n (%)			
No	14 (93.3%)	14 (87.5%)	28 (90.3%)
Yes	1 (6.7%)	2 (12.5%)	3 (9.7%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	14 (93.3%)	14 (87.5%)	28 (90.3%)
Yes	1 (6.7%)	2 (12.5%)	3 (9.7%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	14 (93.3%)	15 (93.8%)	29 (93.5%)

Pseudoaneurysm	1 (6.7%)	0 (0.0%)	1 (3.2%)
Puncture site hematoma	0 (0.0%)	1 (6.3%)	1 (3.2%)
Insulin Use in Hospital Stay,n (%)			
No	14 (93.3%)	12 (75.0%)	26 (83.9%)
Yes	1 (6.7%)	4 (25.0%)	5 (16.1%)
Craniectomy,n (%)			
No	15 (100.0%)	16 (100.0%)	31 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	13 (86.7%)	10 (62.5%)	23 (74.2%)
Yes	2 (13.3%)	6 (37.5%)	8 (25.8%)
Circulation Failure, n (%)			
No	13 (86.7%)	13 (81.3%)	26 (83.9%)
Yes	2 (13.3%)	3 (18.8%)	5 (16.1%)

[1]Chi-Square p-value;

	Center Order 69		
	Group		
	Methylprednisolone (N=6)	Placebo (N=7)	Total (N=13)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (16.7%)	0 (0.0%)	1 (7.7%)
2	1 (16.7%)	0 (0.0%)	1 (7.7%)
3	3 (50.0%)	0 (0.0%)	3 (23.1%)
4	0 (0.0%)	2 (28.6%)	2 (15.4%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (16.7%)	5 (71.4%)	6 (46.2%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	5 (83.3%)	4 (57.1%)	9 (69.2%)
Yes	1 (16.7%)	3 (42.9%)	4 (30.8%)
Missing	0	0	0
Pneumonia,n (%)			
No	6 (100.0%)	0 (0.0%)	6 (46.2%)

Yes	0 (0.0%)	7 (100.0%)	7 (53.8%)
Urinary tract infection,n (%)			
No	5 (83.3%)	7 (100.0%)	12 (92.3%)
Yes	1 (16.7%)	0 (0.0%)	1 (7.7%)
Other Infection,n (%)			
No	6 (100.0%)	7 (100.0%)	13 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	6 (100.0%)	5 (71.4%)	11 (84.6%)
Yes	0 (0.0%)	2 (28.6%)	2 (15.4%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	6 (100.0%)	7 (100.0%)	13 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	5 (83.3%)	6 (85.7%)	11 (84.6%)
Yes	1 (16.7%)	1 (14.3%)	2 (15.4%)
Craniectomy,n (%)			
No	6 (100.0%)	7 (100.0%)	13 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (66.7%)	1 (14.3%)	5 (38.5%)
Yes	2 (33.3%)	6 (85.7%)	8 (61.5%)
Circulation Failure, n (%)			
No	5 (83.3%)	3 (42.9%)	8 (61.5%)
Yes	1 (16.7%)	4 (57.1%)	5 (38.5%)

[1]Chi-Square p-value;

	Center Order		
	70		
	Group		
	Methylprednisolone	Placebo	Total

	(N=2)	(N=2)	(N=4)
modified Rankin Scale score at 90 days,n (%)			
0	2 (100.0%)	0 (0.0%)	2 (50.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	1 (50.0%)	1 (25.0%)
6	0 (0.0%)	1 (50.0%)	1 (25.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	2 (100.0%)	0 (0.0%)	2 (50.0%)
Yes	0 (0.0%)	2 (100.0%)	2 (50.0%)
Urinary tract infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Craniectomy,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Circulation Failure, n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)

[1]Chi-Square p-value;

	Center Order 71		
	Group		
	Methylprednisolone (N=8)	Placebo (N=8)	Total (N=16)
modified Rankin Scale score at 90 days,n (%)			
0	1 (12.5%)	1 (12.5%)	2 (12.5%)
1	1 (12.5%)	1 (12.5%)	2 (12.5%)
2	2 (25.0%)	2 (25.0%)	4 (25.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	1 (12.5%)	2 (25.0%)	3 (18.8%)
5	1 (12.5%)	1 (12.5%)	2 (12.5%)
6	2 (25.0%)	1 (12.5%)	3 (18.8%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (37.5%)	4 (50.0%)	7 (43.8%)
Yes	5 (62.5%)	4 (50.0%)	9 (56.3%)
Urinary tract infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	5 (62.5%)	7 (87.5%)	12 (75.0%)
Yes	3 (37.5%)	1 (12.5%)	4 (25.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	5 (62.5%)	8 (100.0%)	13 (81.3%)
Yes	3 (37.5%)	0 (0.0%)	3 (18.8%)
Craniectomy,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	0 (0.0%)	6 (75.0%)	6 (37.5%)
Yes	8 (100.0%)	2 (25.0%)	10 (62.5%)
Circulation Failure, n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

[1]Chi-Square p-value;

	Center Order 72		
	Group		
	Methylprednisolone (N=7)	Placebo (N=8)	Total (N=15)
modified Rankin Scale score at 90 days,n (%)			
0	1 (14.3%)	0 (0.0%)	1 (6.7%)
1	1 (14.3%)	1 (12.5%)	2 (13.3%)
2	1 (14.3%)	1 (12.5%)	2 (13.3%)

3	2 (28.6%)	1 (12.5%)	3 (20.0%)
4	0 (0.0%)	1 (12.5%)	1 (6.7%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (28.6%)	4 (50.0%)	6 (40.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (100.0%)	4 (57.1%)	11 (78.6%)
Yes	0 (0.0%)	3 (42.9%)	3 (21.4%)
Missing	0	1	1
Pneumonia,n (%)			
No	3 (42.9%)	3 (37.5%)	6 (40.0%)
Yes	4 (57.1%)	5 (62.5%)	9 (60.0%)
Urinary tract infection,n (%)			
No	7 (100.0%)	8 (100.0%)	15 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	6 (85.7%)	8 (100.0%)	14 (93.3%)
Yes	1 (14.3%)	0 (0.0%)	1 (6.7%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	6 (85.7%)	6 (75.0%)	12 (80.0%)
Yes	1 (14.3%)	2 (25.0%)	3 (20.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	7 (100.0%)	8 (100.0%)	15 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	6 (85.7%)	7 (87.5%)	13 (86.7%)
Yes	1 (14.3%)	1 (12.5%)	2 (13.3%)
Craniectomy,n (%)			
No	7 (100.0%)	8 (100.0%)	15 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			

No	5 (71.4%)	3 (37.5%)	8 (53.3%)
Yes	2 (28.6%)	5 (62.5%)	7 (46.7%)
Circulation Failure, n (%)			
No	5 (71.4%)	5 (62.5%)	10 (66.7%)
Yes	2 (28.6%)	3 (37.5%)	5 (33.3%)

[1]Chi-Square p-value;

	Center Order 73		
	Group		
	Methylprednisolone (N=4)	Placebo (N=4)	Total (N=8)
modified Rankin Scale score at 90 days,n (%)			
0	1 (25.0%)	1 (25.0%)	2 (25.0%)
1	0 (0.0%)	1 (25.0%)	1 (12.5%)
2	1 (25.0%)	0 (0.0%)	1 (12.5%)
3	1 (25.0%)	0 (0.0%)	1 (12.5%)
4	1 (25.0%)	1 (25.0%)	2 (25.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	0 (0.0%)	1 (25.0%)	1 (12.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%)
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			

No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

[1]Chi-Square p-value;

	Center Order 74		
	Group		
	Methylprednisolone (N=16)	Placebo (N=15)	Total (N=31)
modified Rankin Scale score at 90 days,n (%)			
0	2 (12.5%)	1 (6.7%)	3 (9.7%)
1	2 (12.5%)	2 (13.3%)	4 (12.9%)
2	5 (31.3%)	2 (13.3%)	7 (22.6%)
3	1 (6.3%)	3 (20.0%)	4 (12.9%)
4	2 (12.5%)	0 (0.0%)	2 (6.5%)
5	0 (0.0%)	1 (6.7%)	1 (3.2%)
6	4 (25.0%)	6 (40.0%)	10 (32.3%)
Missing	0	0	0

Symptomatic intracranial hemorrhage, n (%)			
No	15 (93.8%)	13 (86.7%)	28 (90.3%)
Yes	1 (6.3%)	2 (13.3%)	3 (9.7%)
Missing	0	0	0
Pneumonia,n (%)			
No	8 (50.0%)	6 (40.0%)	14 (45.2%)
Yes	8 (50.0%)	9 (60.0%)	17 (54.8%)
Urinary tract infection,n (%)			
No	16 (100.0%)	12 (80.0%)	28 (90.3%)
Yes	0 (0.0%)	3 (20.0%)	3 (9.7%)
Other Infection,n (%)			
No	16 (100.0%)	15 (100.0%)	31 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	14 (87.5%)	15 (100.0%)	29 (93.5%)
Yes	2 (12.5%)	0 (0.0%)	2 (6.5%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	16 (100.0%)	13 (86.7%)	29 (93.5%)
Pseudoaneurysm	0 (0.0%)	1 (6.7%)	1 (3.2%)
Puncture site hematoma	0 (0.0%)	1 (6.7%)	1 (3.2%)
Insulin Use in Hospital Stay,n (%)			
No	11 (68.8%)	13 (86.7%)	24 (77.4%)
Yes	5 (31.3%)	2 (13.3%)	7 (22.6%)
Craniectomy,n (%)			
No	16 (100.0%)	14 (93.3%)	30 (96.8%)
Yes	0 (0.0%)	1 (6.7%)	1 (3.2%)
Respiration Failure,n (%)			
No	12 (75.0%)	10 (66.7%)	22 (71.0%)
Yes	4 (25.0%)	5 (33.3%)	9 (29.0%)
Circulation Failure, n (%)			
No	15 (93.8%)	11 (73.3%)	26 (83.9%)
Yes	1 (6.3%)	4 (26.7%)	5 (16.1%)

[1]Chi-Square p-value;

	Center Order 75		
	Group		
	Methylprednisolone (N=49)	Placebo (N=49)	Total (N=98)
modified Rankin Scale score at 90 days,n (%)			
0	3 (6.1%)	4 (8.2%)	7 (7.1%)
1	4 (8.2%)	9 (18.4%)	13 (13.3%)
2	13 (26.5%)	10 (20.4%)	23 (23.5%)
3	7 (14.3%)	7 (14.3%)	14 (14.3%)
4	5 (10.2%)	3 (6.1%)	8 (8.2%)
5	3 (6.1%)	3 (6.1%)	6 (6.1%)
6	14 (28.6%)	13 (26.5%)	27 (27.6%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	42 (87.5%)	42 (85.7%)	84 (86.6%)
Yes	6 (12.5%)	7 (14.3%)	13 (13.4%)
Missing	1	0	1
Pneumonia,n (%)			
No	27 (55.1%)	20 (40.8%)	47 (48.0%)
Yes	22 (44.9%)	29 (59.2%)	51 (52.0%)
Urinary tract infection,n (%)			
No	48 (98.0%)	47 (95.9%)	95 (96.9%)
Yes	1 (2.0%)	2 (4.1%)	3 (3.1%)
Other Infection,n (%)			
No	47 (95.9%)	48 (98.0%)	95 (96.9%)
Yes	2 (4.1%)	1 (2.0%)	3 (3.1%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	48 (98.0%)	47 (95.9%)	95 (96.9%)
Yes	1 (2.0%)	2 (4.1%)	3 (3.1%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	1 (2.0%)	1 (1.0%)

No	45 (91.8%)	45 (91.8%)	90 (91.8%)
Pseudoaneurysm	3 (6.1%)	1 (2.0%)	4 (4.1%)
Puncture site hematoma	1 (2.0%)	2 (4.1%)	3 (3.1%)
Insulin Use in Hospital Stay,n (%)			
No	35 (71.4%)	44 (89.8%)	79 (80.6%)
Yes	14 (28.6%)	5 (10.2%)	19 (19.4%)
Craniectomy,n (%)			
No	49 (100.0%)	46 (93.9%)	95 (96.9%)
Yes	0 (0.0%)	3 (6.1%)	3 (3.1%)
Respiration Failure,n (%)			
No	31 (63.3%)	38 (77.6%)	69 (70.4%)
Yes	18 (36.7%)	11 (22.4%)	29 (29.6%)
Circulation Failure, n (%)			
No	43 (87.8%)	43 (87.8%)	86 (87.8%)
Yes	6 (12.2%)	6 (12.2%)	12 (12.2%)

[1]Chi-Square p-value;

	Center Order		
	76		
	Group		
	Methylprednisolone	Placebo	Total
	(N=8)	(N=8)	(N=16)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (12.5%)	2 (25.0%)	3 (18.8%)
2	2 (25.0%)	1 (12.5%)	3 (18.8%)
3	1 (12.5%)	2 (25.0%)	3 (18.8%)
4	1 (12.5%)	1 (12.5%)	2 (12.5%)
5	1 (12.5%)	0 (0.0%)	1 (6.3%)
6	2 (25.0%)	2 (25.0%)	4 (25.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	6 (75.0%)	8 (100.0%)	14 (87.5%)
Yes	2 (25.0%)	0 (0.0%)	2 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			

No	6 (75.0%)	4 (50.0%)	10 (62.5%)
Yes	2 (25.0%)	4 (50.0%)	6 (37.5%)
Urinary tract infection,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Craniectomy,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Respiration Failure,n (%)			
No	5 (62.5%)	6 (75.0%)	11 (68.8%)
Yes	3 (37.5%)	2 (25.0%)	5 (31.3%)
Circulation Failure, n (%)			
No	7 (87.5%)	5 (62.5%)	12 (75.0%)
Yes	1 (12.5%)	3 (37.5%)	4 (25.0%)

[1]Chi-Square p-value;

	Group		
	Methylprednisolone	Placebo	Total

	(N=2)	(N=2)	(N=4)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (50.0%)	1 (25.0%)
2	0 (0.0%)	1 (50.0%)	1 (25.0%)
3	1 (50.0%)	0 (0.0%)	1 (25.0%)
4	1 (50.0%)	0 (0.0%)	1 (25.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	1 (50.0%)	1 (50.0%)	2 (50.0%)
Yes	1 (50.0%)	1 (50.0%)	2 (50.0%)
Urinary tract infection,n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Other Infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	1 (50.0%)	2 (100.0%)	3 (75.0%)
Yes	1 (50.0%)	0 (0.0%)	1 (25.0%)

Craniectomy,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Circulation Failure, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

	Center Order 78		
	Group		
	Methylprednisolone (N=5)	Placebo (N=5)	Total (N=10)
modified Rankin Scale score at 90 days,n (%)			
0	1 (20.0%)	0 (0.0%)	1 (10.0%)
1	1 (20.0%)	0 (0.0%)	1 (10.0%)
2	1 (20.0%)	3 (60.0%)	4 (40.0%)
3	1 (20.0%)	0 (0.0%)	1 (10.0%)
4	1 (20.0%)	0 (0.0%)	1 (10.0%)
5	0 (0.0%)	1 (20.0%)	1 (10.0%)
6	0 (0.0%)	1 (20.0%)	1 (10.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	5 (100.0%)	5 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (80.0%)	3 (60.0%)	7 (70.0%)
Yes	1 (20.0%)	2 (40.0%)	3 (30.0%)
Urinary tract infection,n (%)			
No	5 (100.0%)	5 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (80.0%)	5 (100.0%)	9 (90.0%)

Yes	1 (20.0%)	0 (0.0%)	1 (10.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	5 (100.0%)	5 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	5 (100.0%)	5 (100.0%)	10 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (80.0%)	5 (100.0%)	9 (90.0%)
Yes	1 (20.0%)	0 (0.0%)	1 (10.0%)
Craniectomy,n (%)			
No	5 (100.0%)	5 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	5 (100.0%)	4 (80.0%)	9 (90.0%)
Yes	0 (0.0%)	1 (20.0%)	1 (10.0%)
Circulation Failure, n (%)			
No	5 (100.0%)	4 (80.0%)	9 (90.0%)
Yes	0 (0.0%)	1 (20.0%)	1 (10.0%)

	Center Order 79		
	Group		
	Methylprednisolone (N=14)	Placebo (N=13)	Total (N=27)
modified Rankin Scale score at 90 days,n (%)			
0	1 (7.1%)	1 (7.7%)	2 (7.4%)
1	3 (21.4%)	2 (15.4%)	5 (18.5%)
2	1 (7.1%)	1 (7.7%)	2 (7.4%)
3	3 (21.4%)	2 (15.4%)	5 (18.5%)
4	2 (14.3%)	2 (15.4%)	4 (14.8%)
5	0 (0.0%)	2 (15.4%)	2 (7.4%)
6	4 (28.6%)	3 (23.1%)	7 (25.9%)

Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	14 (100.0%)	12 (92.3%)	26 (96.3%)
Yes	0 (0.0%)	1 (7.7%)	1 (3.7%)
Missing	0	0	0
Pneumonia,n (%)			
No	5 (35.7%)	3 (23.1%)	8 (29.6%)
Yes	9 (64.3%)	10 (76.9%)	19 (70.4%)
Urinary tract infection,n (%)			
No	14 (100.0%)	13 (100.0%)	27 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	13 (92.9%)	13 (100.0%)	26 (96.3%)
Yes	1 (7.1%)	0 (0.0%)	1 (3.7%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	11 (78.6%)	12 (92.3%)	23 (85.2%)
Yes	3 (21.4%)	1 (7.7%)	4 (14.8%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	14 (100.0%)	13 (100.0%)	27 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	10 (71.4%)	12 (92.3%)	22 (81.5%)
Yes	4 (28.6%)	1 (7.7%)	5 (18.5%)
Craniectomy,n (%)			
No	14 (100.0%)	13 (100.0%)	27 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	7 (50.0%)	6 (46.2%)	13 (48.1%)
Yes	7 (50.0%)	7 (53.8%)	14 (51.9%)
Circulation Failure, n (%)			

No	11 (78.6%)	11 (84.6%)	22 (81.5%)
Yes	3 (21.4%)	2 (15.4%)	5 (18.5%)

	Center Order 80		
	Group		
	Methylprednisolone (N=8)	Placebo (N=8)	Total (N=16)
modified Rankin Scale score at 90 days,n (%)			
0	2 (25.0%)	1 (12.5%)	3 (18.8%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	3 (37.5%)	3 (18.8%)
3	1 (12.5%)	2 (25.0%)	3 (18.8%)
4	2 (25.0%)	2 (25.0%)	4 (25.0%)
5	2 (25.0%)	0 (0.0%)	2 (12.5%)
6	1 (12.5%)	0 (0.0%)	1 (6.3%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (50.0%)	2 (25.0%)	6 (37.5%)
Yes	4 (50.0%)	6 (75.0%)	10 (62.5%)
Urinary tract infection,n (%)			

No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Pseudoaneurysm	0 (0.0%)	1 (12.5%)	1 (6.3%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (50.0%)	5 (62.5%)	9 (56.3%)
Yes	4 (50.0%)	3 (37.5%)	7 (43.8%)
Craniectomy,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Respiration Failure,n (%)			
No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Circulation Failure, n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

[1]Chi-Square p-value;

	Center Order		
	81		
	Group		
	Methylprednisolone (N=8)	Placebo (N=8)	Total (N=16)
modified Rankin Scale score at 90 days,n (%)			

0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	2 (25.0%)	1 (12.5%)	3 (18.8%)
2	1 (12.5%)	1 (12.5%)	2 (12.5%)
3	2 (25.0%)	2 (25.0%)	4 (25.0%)
4	1 (12.5%)	1 (12.5%)	2 (12.5%)
5	1 (12.5%)	1 (12.5%)	2 (12.5%)
6	1 (12.5%)	2 (25.0%)	3 (18.8%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (87.5%)	5 (62.5%)	12 (75.0%)
Yes	1 (12.5%)	3 (37.5%)	4 (25.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	7 (87.5%)	3 (37.5%)	10 (62.5%)
Yes	1 (12.5%)	5 (62.5%)	6 (37.5%)
Urinary tract infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	5 (62.5%)	7 (87.5%)	12 (75.0%)
Yes	3 (37.5%)	1 (12.5%)	4 (25.0%)
Craniectomy,n (%)			
No	7 (87.5%)	8 (100.0%)	15 (93.8%)

Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Respiration Failure,n (%)			
No	7 (87.5%)	5 (62.5%)	12 (75.0%)
Yes	1 (12.5%)	3 (37.5%)	4 (25.0%)
Circulation Failure, n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)

[1]Chi-Square p-value;

	Center Order		
	82		
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (50.0%)	2 (25.0%)
1	1 (25.0%)	1 (25.0%)	2 (25.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	2 (50.0%)	1 (25.0%)	3 (37.5%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%)
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%)
Urinary tract infection,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%)
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Craniectomy,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Respiration Failure,n (%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%)
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%)
Circulation Failure, n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

[1]Chi-Square p-value;

	Center Order		
	Merge of Center 7,16, 19, 21, 30, 31, 47, 50, 54, 57, 63, 66		
	Group		
	Methylprednisolone (N=12)	Placebo (N=18)	Total (N=30)
modified Rankin Scale score at 90 days,n (%)			
0	4 (33.3%)	0 (0.0%)	4 (13.3%)
1	1 (8.3%)	3 (16.7%)	4 (13.3%)
2	2 (16.7%)	4 (22.2%)	6 (20.0%)
3	2 (16.7%)	4 (22.2%)	6 (20.0%)
4	2 (16.7%)	1 (5.6%)	3 (10.0%)

5	0 (0.0%)	1 (5.6%)	1 (3.3%)
6	1 (8.3%)	5 (27.8%)	6 (20.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	11 (91.7%)	12 (66.7%)	23 (76.7%)
Yes	1 (8.3%)	6 (33.3%)	7 (23.3%)
Missing	0	0	0
Pneumonia,n (%)			
No	6 (50.0%)	7 (38.9%)	13 (43.3%)
Yes	6 (50.0%)	11 (61.1%)	17 (56.7%)
Urinary tract infection,n (%)			
No	12 (100.0%)	18 (100.0%)	30 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	12 (100.0%)	18 (100.0%)	30 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	11 (91.7%)	16 (88.9%)	27 (90.0%)
Yes	1 (8.3%)	2 (11.1%)	3 (10.0%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	12 (100.0%)	18 (100.0%)	30 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	7 (58.3%)	16 (88.9%)	23 (76.7%)
Yes	5 (41.7%)	2 (11.1%)	7 (23.3%)
Craniectomy,n (%)			
No	12 (100.0%)	17 (94.4%)	29 (96.7%)
Yes	0 (0.0%)	1 (5.6%)	1 (3.3%)
Respiration Failure,n (%)			
No	8 (66.7%)	13 (72.2%)	21 (70.0%)
Yes	4 (33.3%)	5 (27.8%)	9 (30.0%)

Circulation Failure, n (%)			
No	11 (91.7%)	14 (77.8%)	25 (83.3%)
Yes	1 (8.3%)	4 (22.2%)	5 (16.7%)

[1]Chi-Square p-value;

eFigures

eFigure 1. Flowchart



eFigure 2. Distribution of 82 Enrolling Centers in 17 Provinces in China

Shown was the distribution of the 82 enrolling centers in 17 Provinces in China.

eFigure 3. Distribution of the Modified Rankin Scale Score at 90 Days (Per-protocol Population).



The distribution of the modified Rankin scale score among patients in the tirofiban group and the aspirin group. Scores range from 0 to 6, with 0 indicating no symptoms, 1, no clinically significant disability, 2, slight disability, 3, moderate disability, 4, moderately severe disability, 5, severe disability, and 6, death. Numbers indicate rounded proportions.7 patients lost to follow up were not included in the per-protocol analysis.

eFigure 4. Kaplan-Meier Estimates of Survival Probability (Full Analysis Set)



Adjusted Hazard Ratio was 0.82; 95% Confidence Interval, 0.71 to 0.93, P = 0.003). The proportional harzard assumption was satisfied (p > 0.05). Cox regression model was adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method.

eFigure 5. Subgroup Analysis of Death (Safety Population).



* Interactions of methylprednisolone treatment effect with each of the subgroup variables was explored by adding interactions of the subgroup variables with treatment to the modified Poisson regression. The models were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method and were not adjusted for multiple comparisons.

eFigure 6 Subgroup Analysis of sICH (Safety Population).

Subgroup	No. of patients	Methylprednisolone group Events, n/N (%)	Placebl group Events, n/N (%)	Adjusted RR (95% CI)
Overall	1653	71/823 (8.63)	97/830 (11.69)	0.74 (0.55 to 0.99)
Age				
≤ 69	861	31/443 (7)	48/418 (11.48)	0.6 (0.39 to 0.93)
> 69	792	40/380(10.53)	49/412 (11.89)	0.88 (0.59 to 1.3)
Sex				
Female	715	31/352 (8.81)	38/363 (10.47)	0.84 (0.53 to 1.32)
Male	938	40/471 (8.49)	59/467 (12.63)	0.68 (0.46 to 0.99)
Baseline NIHSS score				
≤ 19	923	38/462 (8.23)	45/461 (9.76)	0.86 (0.57 to 1.29)
> 19	730	33/361 (9.14)	52/369 (14.09)	0.64 (0.42 to 0.97)
Pre−stroke mRS				
0	1593	67/787 (8.51)	92/806 (11.41)	0.75 (0.56 to 1.01)
1	42	2/28 (7.14)	5/14 (35.71)	0.19 (0.04 to 0.86)
2 or more	18	0/10 (0.00)	2/8 (25.00)	–
Baseline ASPECTS score				
≤ 5	807	47/406 (11.58)	55/401 (13.72)	0.85 (0.59 to 1.22)
> 5	841	23/414 (5.56)	41/427 (9.6)	0.58 (0.35 to 0.95)
Intravenous Thrombolysis				
Yes	615	18/285 (6.32)	37/330 (11.21)	0.58 (0.34 to 1)
No	1038	53/538 (9.85)	60/500 (12.00)	0.82 (0.58 to 1.17)
Time from stroke onset to randomization (min)				
≤ 362	829	34/418 (8.13)	44/411 (10.71)	0.76 (0.5 to 1.17)
> 362	824	37/405 (9.14)	53/419 (12.65)	0.72 (0.49 to 1.08)
Occlusion Location				
ICA	567	26/277 (9.39)	45/290 (15.52)	0.6 (0.38 to 0.94)
M1	866	36/446 (8.07)	37/420 (8.81)	0.91 (0.58 to 1.41)
M2	218	9/98 (9.18)	15/120 (12.50)	0.75 (0.34 to 1.64)
Reperfusion				
Yes	1180	41/592 (6.93)	58/588 (9.86)	0.71 (0.48 to 1.04)
No	471	30/230 (13.04)	38/241 (15.77)	0.81 (0.52 to 1.27)
COVID				
Control	885	29/440 (6.59)	54/445 (12.13)	0.54 (0.35 to 0.83)
Exposed	768	42/383 (10.97)	43/385 (11.17)	0.99 (0.66 to 1.49)



* Interactions of methylprednisolone treatment effect with each of the subgroup variables were explored by adding interactions of the subgroup variables with treatment to the modified Poisson regression. The models were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method and were not adjusted for multiple comparisons.